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INTRODUCTION 
 
Diabetes mellitus, the most common endocrine disorder is characterised by 
metabolic abnormalities and long-term microvascular and macrovascular 
complications. 
The prevalence of diabetes is on the rise, more alarming in the developing 
countries. Besides multiplying risk for coronary heart disease, diabetes enhances the 
incidences of cerebrovascular accidents. Moreover it is the leading cause of 
acquired blindness and accounts for about a quarter of the cases with end stage 
renal disease as well as half of the cases of non-traumatic lower limb amputations 
Diabetic nephropathy occurs in as many as 30% of Type I diabetes mellitus 
patients and 25% of Type IIdiabetes mellitus patients. Diabetic nephropathy is a 
dreaded disease with progressive and continuous deterioration in glomerular 
function resulting in irreversible renal failure. Diabetic nephropathy is an important 
cause of morbidity and mortality and is now among the most common cause of end 
stage renal disease. However there is an early phase of diabetic renal disease called 
incipient diabetic nephropathy. In this stage there is a rise in urinary excretion of 
albumin i.e. microalbuminuria. But the rise is detectable only by use of sensitive 
assay for urinary albumin. At this stage urine is negative for macro albumin and renal 
function is normal by standard clinical tests. The presence of microalbuminuria 
precedes the development of overt diabetic nephropathy by 10 to 15 years. It is at 
this stage that one can hope to reverse diabetic renal disease or prevent its 
progression. Therapeutic interventions which reverse microalbuminuria include 
intensified insulin treatment, dietary protein restriction,and control of hypertension by 
ACE inhibitors and Beta-blockers. 
Microalbuminuria thus is an important warning sign for both the physician and 
the patient which if ignored can lead to irreversible renal damage. 
Microalbuminuria is most commonly associated with other microvascular 
complications of diabetes namely retinopathy, neuropathy, and ischemic heart 
disease. So microalbuminuria may be a marker for widespread microvascular 
damage in a patient of diabetes mellitus. 
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The aim of this study was to study the occurrence of microalbuminuria in 
patients with Type IIdiabetes mellitus and also to find out it its association with the 
risk factors of diabetes mellitus and the microvascular complications and 
macrovascular complications of diabetes mellitus 
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OBJECTIVES 
 
 
Ø To find the association between microalbuminuria and its risk factors 
and complications in south Indian type II Diabetes population attending 
PSGIMS&R, Peelamedu,  
 
Ø Coimbatore,Tamil Nadu. 
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REVIEW OF LITERATURE 
HISTORICAL REVIEW: 
 
1.Diabetes mellitus: 
The knowledge of diabetes dates back to centuries before Christ. Polyuric disease, 
resembling diabetes was described as early as 150 BC in ancient Egyptian records 
discovered by George Beers. Celsius (30BC-50AD) had recognized the 
disease.Diabetes, a Greek term, which literally means to ‘run thru’ or a ‘siphon’ was 
initiallyused by Aretaeus in first century AD for the generic description of a condition 
causing increased urine output1. Roman physicians thought of diabetes as a 
“wonderful affection, not very frequent among men, being melted down of flesh and 
limbs into urine.  
The association of polyuria with a sweet tasting substance in the urine was 
first reported in Sanskrit literature dating from fifth to sixth centuries AD at the time of 
two noted Indian physicians Susruth and Charaka4. It was in the seventeenth 
century that Thomas Willis (1621-1675) made the observation “ as if imbibed with 
honey and sugar about the diabetic urine”. A century after Willis, Mathew Dobson 
(1735-1784) demonstrated that the sweetness of urine was indeed due to sugars. It 
was John Rollo who was one of the first to use the adjectivemellitus (mellitus = 
honey) to distinguish it from other polyuric states in which the urine was unsavory 
(Greek – insipidus). Over the centuries, gradually the causes and complications of 
this disease were recognized. Aricanne, an Arab physician at around the tenth 
century had described gangrene 2, 3. 
The diabetes world was overwhelmed with joy in 1921 when young physician 
and surgeon Fredrick Grant Banting (1891-1941) and Charles.H.Best, his graduate 
student assistant, working in Toronto through the summer on an almost non-existent 
budget in a lab loaned to them temporarily by a vacating professor, prepared active 
extracts ofpancreas which lowered the elevated level of sugars in diabetic dogs. 
The first patient to be treated with pancreatic extract was Leonard Thomson in 
1922.The long acting insulin preparation (isophane) was introduced in 1936 by Hans 
12 
 
Christian Hagedorn and colleagues. The testing of Sulfonylureas was done by 
Auguste Loubatieries in 1944.Thefirst therapeutic use of a Biguanide was done by 
G.Ungar in 1957.The efficacy of insulin in preventing the complications and retarding 
multisystem involvement was heralded by the fact that the untreated cases in the 
pre-insulin era had a high mortality rate which wasmostly due to diabetic 
ketoacidosis2, 3. 
 
2.Diabetic nephropathy: 
Diabetes was for many years regarded as the disease of the kidneys. This 
was the opinion of Aretaeus, Capadcian in second century AD. The view was still 
held by Erasmus Darwin in 1801. The presence of proteinuria in diabetes mellitus 
had long been known. Contunniues (1770), Rollo (1798), Darwin (1801), Rayer 
(1840), Van Noorden(1912), all had described the association of dropsy with 
diabetes. Vacuolization of tubular epithelium was observed by Armani (1875) and 
Ebstein (1881) and was shown to be due to glycogen infiltration by Ehlrich in 1888. 
Kimmelstiel and Wilson were the first to attribute specific glomerular lesions 
entitled inter capillary lesions in the glomeruli of kidney. These peripheral hyaline 
masses are known as Kimmelstiel Wilson lesions. These histological features were 
associatedwith clinical features of diabetes, hypertension, nephrotic syndrome and 
renal failure. 
 
3. Microalbuminuria: 
In 1963 Keen and Chlouvervakis developed sensitive and specific 
Radioimmunoassay for detecting human albumin in low concentration i.e. 
microalbuminuria, which indicate earliest stage of diabetic renal disease. Later 
various other methods were developed for detection of microalbuminuria. 
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INCIDENCE AND PREVALENCE OF MICROALBUMINURIA 
 
 
The prevalence of microalbuminuria in Type I DM patients has been reported 
in range from 5-37% in different population based and diabetic clinic based studies. 
In Type IIDM patients’ prevalence of microalbuminuria have been reported in 
between 8% and 46% in Europeans and 47% in  indians. Microalbuminuria is found 
not only in patients with diabetes but also in patients with impaired glucose 
tolerance. 
 
Age:  
There is no correlation that has been found between Albumin Excretion Rate 
(ARE) and age. 
 
Sex: There is male preponderance in Type I DM patients. There is no correlation 
between microalbuminuria and sex in Type IIDM patients. 
 
Duration of diabetes:  
 
Prevalence increase with duration of Type I DM with distinct variation in the 
rate of increase. Incidence of microalbuminuria is very high during the first 3 years 
after diagnosis of diabetes, declines at the end of first decade of diabetes and then  
increase again to a peak around 12-15 years duration. The prevalence is 8% in 
patientswith Type I DM of only 1-3 years of duration. The prevalence of 
microalbuminuria levels off after 10 years (prevalence of 20%) and then assumes its 
steep climb of around 32% after 30 years of post pubertal duration of diabetes. 
 
 
Glycaemia:  
The level of glycaemic control seems to be the strongest factor influencing 
transition from normoalbuminuria to microalbuminuria. In recent observational study 
ofthe dose response relationship between intensity of hyperglycemia (measuredas 
14 
 
average glycosylated hemoglobin HbA1C level during a 2-4 year period) and the rise 
tomicroalbuminuria was determined in a large cohort of Type I DMpatients. A 
threshold effect of hyperglycemia on the development of microalbuminuria was 
found. Below an HbA1C of 10.1% the risk of persistent microalbuminuria varied little. 
In contrast above a thresholdHbA1c of 10.1% the risk of microalbuminuria rose 
steeply with increasing levels of HbA1c. In comparison the risk of microalbuminuria 
increases six fold faster between HbA1 levels  of 11 and 12% and that between 8 
and 9%. This relationship between HbA1c and levels ofmicroalbuminuria was 
independent of the effect of duration of Type I DM. 
 
Exercise:  
Moderately strenuous exercise can provoke an exaggerated rise in AER in 
patients with diabetes whose resting values are normal. The severity of exercise 
inducedalbuminuria seems to be related to duration of diabetes and is modulated by 
level of glucose control 
 
Blood pressure and heart rate:  
Significant positive associations are found between microalbuminuria and 
diastolic blood pressure and resting heart rate. Other factors influencing the risk of 
developing microalbuminuria includecigarette smoking, elevated levels of serum LDL 
cholesterol49, 50.  
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ETIOPATHOGENESIS 
 
1. Hyperglycaemia: 
The development of clinically overt renal disease is not linearly related to 
duration of diabetes and affects only between 35-50% of patients. The majority of 
patients with diabetes escape renal failure, and although some histological changes 
occur in their kidneys, their renal function remain essentially normal till death.  It 
appears that hyperglycaemia is necessary but not sufficient to cause renal damage 
that leads to kidney failure and that possibly non-environmental factors are needed 
for the manifestation ofthe clinical syndrome. 
2.AGES: 
Glycosylation of tissue proteins also may contribute to the development of 
diabetic nephropathy and other microvascular complications. In chronic 
hyperglycemia, some of the excess glucose combines with free amino acids on 
circulating or tissue proteins. This nonenzymatic process initially forms reversible 
early glycosylation products and later irreversible Advanced Glycosylation End 
Products (AGEs) 
Circulating AGE levels are increased in diabetics, particularly those with renal 
insufficiency, since AGEs are normally excreted in the urine . The net effect is tissue 
accumulation of AGEs, in part by crosslinking with collagen, which can contribute to 
the associated renal and microvascular complications. 
 
There are three possible mechanisms through which non-enzymatic glycation may 
contribute to diabetic complications1. 
 
1) AGE may alter the structure and functions of extracellular matrix by cross-linking 
matrix proteins 
2) AGE may affect the activity of signals such as cytokines, growth factors and free 
radicals, by interacting with AGE receptors on various tissues. 
3) Glycation may directly affect the functions of enzymes and other key intracellular 
proteins1, 25. 
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Recent studies have shown that AGE products bind to specific AGE receptor 
identified by macrophages, endothelial cells and mesangial cells and thus induce the 
synthesis and secretion of cytokines, including Interleukin1 (IL-1) and insulin like 
growth factor 1 (IGF-1) 26,27. This could stimulate the proliferation of mesangial 
cells and also the glomerular synthesis of Type IV collagen28. On the other hand 
advanced glycation 
appears to reduce mitogenic activity of basic fibroblast growth factor (b-FGF) in 
cultured endothelial cells29.  
AGE can induces excessive cross linking of collagen molecules, affecting the 
assembly and architecture of glomerular basement membrane and mesangial cells 
via platelet derived growth factor (PDGF), causing them synthesize more 
extracellular matrix30. All these processes may lead to enhanced deposition of 
extracellular matrix proteins in the mesangium interfere with mesangial clearance of 
macromolecules and alter macrophage function, therefore contributing to mesangial 
expansion and gloemrular  occlusion. AGE has also been shown to quench and 
inactivate nitric oxide (NO), a vasodilator and antiproliferative factor, in a dose 
dependent manner31. 
 
 
3) The polyol pathway: 
Sorbitol is produced in cells from glucose by reaction catalysed by 
aldolasereductase. In the normal kidney aldolase reductase is present in the papilla, 
glomerular  distal tubular cells and also in mesangial cells. In the renal medullary 
cells of the kidney the primary role of aldolase reduction is in the generation of 
Sorbitol, an organic osmolyte in response to high salinity in medullary interstitial. 
Sorbitol would aid in preventing the osmotic stress. Chronic hyperglycaemia may 
lead to Sorbitol accumulation in a variety of tissues including renal tubules and 
glomerular. Sorbitol accumulation could cause tissue damage perhaps by disturbing 
cellular osmoregulation and depleting intracellular myoinositol. Depletion of 
phospoinositidase may result in reduced hydrolysis of phosphotidylinositol bi 
phosphate and decreased diacylglycerol formation. Diacylglycerol is a major 
endogenous cellular mediator of protein kinase C activation which itself has been 
implicated in pathogenesis of diabetic renal disease32. 
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4) Biochemical abnormalities of extracellular matrix: 
Diabetic glomerulopathy is characterised by excessive accumulation of glomerular 
basement membrane and mesangial matrix. Glycosaminoglycans (GAG) 
polysaccharides account for approximately 90% of total carbohydrate component of 
glomerular basement membrane with sialoprotein constituting remainder. The 
principal GAG in the glomerular basement membrane is heparan sulfate that 
together with sialic acid contributes to negative charge of glomerular capillary wall 
and thereby to charge selective properties of the filtration barrier. In diabetes, there 
is reduced de novo synthesis of glomerular heparan sulphate and the totalGAG 
content in the glomerulus and the glomerular basement membrane is reduced. The 
heparan sulphate content of glomerular basement membrane has been found to be 
decreased in patients with Type I DM with nephropathy. Sialoglycoproteins are 
highly negatively charged and coat glomerular epithelial cells, their foot process and 
epithelial slit diaphragm. A loss of negative charge of glomerular membrane may be 
responsible for foot process fusion, with consequent obliteration of the slit diaphragm 
and could partly explain the albuminuria of diabetic nephropathy 30. 
 
5) Glucotoxicity: 
Glucose itself may have direct toxic effects on cells.  Abnormalities include alteration 
in cell replication and maturation associated with evidence of damage to DNA. High 
glucose levels also lead to increased expression and synthesis of collagen, 
fibronectin and laminin, which may partly explain the enhanced products of 
extracellular matrix observed in diabetic kidneys. Mesangial cells in high glucose 
levels induce transcription and secretion ofTGF-B, which is unique among the 
cytokines in that it stimulates the matrix synthesis and inhibits its degradation.  
Abnormalities in endothelial cell function have been implicated in the 
increased frequency of cardiovascular disease that is a feature of diabetic 
nephropathy.  
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6) Hemodynamic and hypertrophic pathways: 
Glomerular hemodynamic disturbances with elevation of renal blood flow and GFR 
occur early in the course of diabetes have been suggested directly responsible for 
development of glomerulosclerosis and attendant proteinuria. Several observations 
support the notion that renal hyper perfusion and hyper filtration contribute to renal 
damage. Elevated intraglomerular pressure via increased mechanical stress and 
shear forces may damage the endothelial surface and disrupt the normal structure of 
glomerular barrier, and could eventually lead to mesangial proliferation, increased 
production of extracellular matrix and thickening of glomerular basement membrane. 
Hemodynamic abnormalities are usually associated with hypertrophic 
changes in glomerulus. Marked renal hypertrophy is an early event in diabetes and it 
is argued that hyperplastic and hypertrophic changes in diabetic kidney may precede 
the hemodynamic abnormalities. Chronic overexpression of growth hormone or 
growth hormone releasing factors may lead to early glomerular enlargement followed 
by glomerulosclerosis. Growth hormone, insulin like growth factors, TGF-B, PDGF 
and other growth promoters may trigger mesangial cell proliferation and increase in 
mesangial matrix synthesis (and/or decrease its degradation), so causing 
pathognomonic features of diabetic glomerulopathy32. 
 
7) Familial and genetic pathways: 
Diabetes induces important metabolic, hormonal and growth factor changes. These 
changes that are related in part to the degree of glycaemic control, occur in virtually 
all patients, but till now it has been impossible to isolate a subset of individuals in 
whom the severity of these environmental perturbations is convincingly linked to 
development of these complications. On the contrary, there is ever growing evidence 
that the diabetic control is only a necessary component but is not linearly related to 
development of renal failure. To explain the susceptibility of renal failure in a 
subgroup of patients who develop renal failure alternative hypothesis has been 
advocated taking into account the host response to diabetic induced environmental 
disturbances. 
Familial clustering of diabetic kidney disease has been reported. In Type I DM 
83% of siblings of proband with diabetic nephropathy haveevidence of nephropathy, 
compared with only 17% of diabetic sibling of probands without nephropathy36. 
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Familial influence on development of nephropathy has been described in Pima 
Indians with Type II DM 
  
Sodium Lithium counter transport: Genetically determined red cell sodium-
lithium counter transport, a cell membrane cation transport system whose elevated 
levels are associated with essential hypertension has given insight into 
predisposition to diabetic renal disease and also attendant cardiovascular disease38. 
The rate of sodium-lithium counter transport has been found to be higher in 
proteinuric patients with diabetes than in normoalbuminuric controls. 
Microalbuminuric diabetic patients have also been found to have higher sodium-
lithium counter transport activity. Higher rate of counter transport were associated 
with elevated LDL cholesterol, total and VLDL triglycerides and reduced HDL 
cholesterol concentrations. The mechanism of association between sodium lithium 
counter transport activity, hypertension and lipid abnormalities and susceptibility to 
diabetic renal and vascular disease could be insulin resistant state. 
These associations (i.e. albuminuria, left ventricular and renal hypertrophy 
and insulin resistance) were independent of actual level of blood pressure or 
duration of arterial hypertension. This combination of risk factors may not be 
confined to diabetic population but may be a manifestation of syndrome in general 
population (Syndrome X) 
39, 40. 
 
Sodium-hydrogen antiporter: Sodium-hydrogen antiporter is a cell membrane 
cation exchanger that catalyses the electroneural exchange of extracellular sodium 
ions for intracellular hydrogen ions with a stociometry of 1:1. Molecular ionic studies 
have so far revealed the presence of five subtypes of sodium hydrogen 
exchangers41. 
The most widely studied sodium isoform is referred to as NHE-1, is expressed 
ubiquitously. The gene for NHE-1is located on short arm of chromosome 1; and 
encodes a protein of B15 amino acid with two distinct domains. Increased sodium-
hydrogen antiport activity has been reported in leucocytes of Type I DM patients with 
nephropathy as well as patients with essential hypertension and on red cells from 
Type I DM patients with microalbuminuria. The  cells of diabetic patients who 
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develop nephropathy have intrinsic enhanced capacity to proliferate and this 
phenomenon is associated with high rates of sodium hydrogen exchange activity. 
The activity of sodium hydrogen antiport seems to act as an indicator of some 
mechanism possibly genetically determined controlling cell growth and 
hypertrophy on one hand and intracellular homeostasis on the other. The 
environmental changes brought about by diabetes could lead to dysregulation of 
these mechanisms in susceptible individuals and induces cell hypertrophy and 
hyperplasia contributing to glomerular hypertrophy and mesangial expansion in the 
kidneys as well as tubular hypertrophy and hyperplasia. Increased renal sodium 
reabsorption would augment systemic and renal perfusion pressure to maintain 
sodium balance. The increasedperfusion pressure would be readily transmitted to 
glomerular capillaries because of generalised vasodilatation present in diabetes. 
This would lead to increased intraglomerular pressure, which determines at least in 
part, and increase in GFR may be responsible for disruption of glomerular 
permeability properties generating proteinuria. On the other hand progressive 
mesangial expansion would lead to glomerulosclerosis and further disruption of 
glomerular basement membrane permeability selective properties. The insulin 
resistance associated with excessive growth and the consequent hyperinsulinemia 
may cause lipid abnormalities that in the setting of vascularhyperpermeability 
characteristic of diabetic microvascular disease, would further aggravate the renal 
histological damage and contribute in combination with hypertension, and 
accelerated atherosclerosis of diabetic renal failure42, 43, 44. 
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PATHOLOGY 
Appearence: 
Gross Appearance: 
The kidneys are of usually normal size. They may be enlarged in the early 
stages, but later becomes contracted with granular surface. The cut surface is 
usually pale and the renal arteries may show arteriosclerosis later stages. 
 
Light microscopy: 
Glomerular lesions1, 45, 46, 47: 
1) Nodular 
2) Diffuse 
3) Exudative 
4) Glomerular hyalinization 
 
Nodular lesions: 
The nodular lesions described by Kimmelstiel and Wilson in 1936 has for a 
long time been considered virtually specific for diabetes. 
The nodules are well-demarcated hard masses, eosinophilic, and periodic acid schiff 
positive, located in the central regions of peripheral lobules. When not acellular they 
contain pyknotic nuclei and infrequently foam cells can be seen surrounding them.  
They are characteristically 
irregular in size and distribution, both within and between glomerular loops and 
located away from the hilus. A rim of mesangial cells can sometimes be seen 
between them and adjoining capillary, which is often distended. Recent evidence 
seems to establish mesangium as their site of origin and extends the original 
suggestion that mesangial disruption and lysis of lobule center was related to prior 
microaneurysmal dilatation of the associated capillary followed by a laminar 
reorganization of mesangial debris. Its incidence varies considerably from 12-46% in 
different series, which included both Type I DM and Type II DM cases. Nodules are 
not seen in the absence of diffuse lesions, and this reflects their appearance only 
after a long period of disease. 
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Diffuse glomerular lesions:  
Diffuse glomerular lesions comprise an increase in mesangial area and 
capillary wall thickening with the mesangial matrix extending to involve the capillary 
loops. The accumulated material has staining properties similar to those of nodules. 
In its early stages it may be difficult to distinguish the minor mesangialexpansion 
from changes present with aging or from other glomerular pathology. In more severe 
cases capillary wall thickening and mesangial expansion lead to capillary narrowing 
and eventually to complete hyalinization. In advanced lesions periglomerular fibrosis 
is often present. As with nodules the distribution of diffuse lesion is non-uniform, both 
among lobules of the same glomerulus and between different glomeruli, leading to 
appearances suggestive of transition to nodule formation. The thickening of capillary 
walls also tends to be non-uniform, and this is particularly evident when the 
histological changes are notvery severe. The diffuse lesions represent earlier stage 
in the evolution of the disease. In patients with Type II DM the reported prevalence of 
these changes ranges between 25-51%. 
 
Exudative Glomerular lesions: 
Exudative lesions are highly eosinophilic rounded homogenous structures 
seen in capsular space overlying a capillary loop (fibrin cap) or lying on the inside of 
Bowman’s capsule (capsular drop). They are non-specific, containing various 
proteins and sometimes lipid materials. 
 
Glomerular hyalinization: 
 As a consequence of above lesions increasing number of  glomeruli becomes 
hyalinised in advanced cases. In some of the ischemic glomeruli, the tufts shrink with 
fibrous thickening of the inner surface of Bowman’s capsule. 
 
Arterial lesions:  
Diffuse intimal fibrosis in these vessels has been found to be more frequent  
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Arteriolar lesions:  
Arteriolar lesions are prominent in diabetics with hyaline material 
progressively replacing the entire wall structure.Both afferent and efferent arterioles 
could be affected. Bell also established lesions were often present in absence of 
hypertension and the involvement of efferent vessel was highly specific for diabetes. 
These arteriolar changes may be the first change detectable by light microscopy in 
the diabetic kidney as judged by their recurrence at 2 years in non-diabetic kidneys 
transplanted into diabetic patients. 
 
Tubular and interstitial changes:  
Tubules and interstitium may show a variety of changes that are non-specific 
and similar to those seen in other forms of progressive renaldisease.  
Armanni-Ebstien lesions are the result of accumulation of glycogen in tubular 
cells of the corticomedullary region in patients with profound glycosuria. More subtle 
tubular changes consisting of vacuolization, a decrease in the intercellular spaces 
normally present between the macula densa and a significant increase in the contact 
areabetween them and extraglomerular mesangial cell48. 
Immunopathology: 
Westberg and Michael confirmed previous observation of linear staining of 
glomerular basement membrane for IgG, IgM, albumin and fibrinogen in kidneys of 
patients with IDDM. The findings were later extended for IgG and albumin not only 
inthe glomerular basement membrane but also in the Bowman’s capsule and 
especially in the outer aspect of tubular basement membrane were considered 
specific for diabetes. 
Immunofluoroscence techniques have shown increased mesangial amounts 
of type I, IV, V and VI collagens. Immunochemical analysis has also showed reduced 
levels laminin and markedly decreased amounts of heparan sulphates, proteoglycan 
where as levels of fibronectin were normal in diabetic mesangium. 
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Electron microscopy: 
Salient features are: 
1) Thickening of glomerular basement membrane 
2) Maintenance of fine detail of epithelial foot process and abundant epithelial 
cytoplasm containing enlarged mitochondria. 
3) Accumulation of basement membrane like material within the mesangium. 
4) Fibrin deposition in the mesangium and along endothelial aspect of capillary 
basement membrane. 
 
Structure-function relationship: 
In early phases of IDDM the increase in luminal volume and filtration surface 
area may explain the increase in GFR. With advancing renal disease, a close 
association is observed between thefunctional changes and mesangial expansion 
but not thickness of glomerular basement membrane. Mesangial expansion also 
correlates inversely with capillary filtration surface area, a variable closely associated 
with glomerular filtration rate from levels of hyperfiltration to markedly reduce renal 
function. Therefore it has been suggested that expansion of mesangium with 
attendant reduction in glomerular filtration surface areathat is responsible for the 
progressive loss of renal function in Type I DM 
In Type I DMpatients with low levels of microalbuminuria (i.e. AER of 20-
30mcg/min) no consistent glomerular abnormalities have been found. Above these 
levels of urinary albumin excretion, however the fractional volume of mesangium is 
on averagesignificantly increased, and minor reduction in creatinine clearance and 
rise in bloodpressure are observed. Similar findings have been reported in Type II 
DM patients withmicroalbuminuria and proteinuria47. 
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HISTOPATHOLOGY OF DIABETIC NEPHROPATHY 
DIABETIC NEPHROPATHY 
 
Light micrograph showing diffuse and 
nodular (N) glomerulosclerosis in 
diabetic nephropathy. Note the dense 
appearance of the deposits and the 
rim of cells around the nodules. 
 
 
 
 
 
 
 
 
ADVANCED DIABETIC NEPHROPATHY 
 
Light micrograph in advanced 
diabetic nephropathy shows diffuse 
and nodular mesangial expansion 
and characteristic hyaline thickening 
of the arteriole at the glomerular 
hilum (arrow). Although not shown, 
diabetes typically affects both  
afferent and efferent arterioles. 
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Basement membrane thickening in diabetic nephropathy 
 
Electron micrograph in diabetic 
nephropathy shows a 2 to 3 
fold increase in the thickness of 
the glomerular basement 
membrane (GBM). Although 
not seen, the mesangium is also 
expanded by basement 
membrane-like material, a 
process that contributes to 
nodule formation and 
glomerulosclerosis. 
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STAGES OF DIABETIC NEPHROPATHY 
 
Diabetic nephropathy can conveniently be categorized into different stages, 
which differ with respect to renal hemodynamic, systemic blood pressure, urinary 
findings and susceptibility to therapeutic interventions. 
 
 
Stages of diabetic nephropathy- typical findings49 
 
STAGE GFR ALBUMINURIA 
Mcg/ml 
BP YERAS 
AFTER 
DIAGNOSIS 
RENAL 
HYPERFUNCTION 
 
Elevated 
 
Absent 
 
Normal 
 
At diagnosis 
 
CLINICAL LATENCY 
 
High normal 
 
Absent 
 
Normal 
 
At diagnosis 
 
MICROALBUMINURIA 
 
With in    
normal 
range 
 
20-200 
 
within  
or >normal 
 
5-15 
MACROALBUMINURIA Decreasing >200 Increased 10-15 
END STAGE 
NEPHROPATHY 
diminished massive increased 15-30 
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PROGNOSTIC SIGNIFICANCE OF MICROALBUMINURIA 
 
Prevalence —  
The reported prevalence of microalbuminuria among patients with type 2 
diabetes approximately 10 years after the diagnosis ranges from 25 to 40 percent 
[16-20] . In a systematic review of 28 studies in type 2 diabetes (10,298 patients), the 
prevalence of microalbuminuria was 26 percent at a mean diabetes duration of 10 
years [16] . The prevalence was similar (27 percent at eight years) in the ADVANCE 
trial of 11,140 patients with type 2 diabetes that was published after the systematic 
review [17] . 
The prevalence of microalbuminuria in patients with type 2 diabetes varies 
with ethnicity, being higher in Asians and Hispanics than in whites [19,20] . The 
magnitude of this difference was illustrated in an international cross-sectional study 
of over 24,000 patients with type 2 diabetes without known albuminuria [20] . At a 
mean duration of diabetes of almost eight years, the rate of microalbuminuria was 
significantly higher in Asians and Hispanics (43versus 33 percent in whites). As 
noted in the following section,there arealso racial and ethnic differences in the rate of 
progression to macroalbuminuria.Some patients with type 2 diabetes have 
microalbuminuria at the time of diagnosis [18,21,22] .  
A higher rate of microalbuminuria (17.9 percent) was noted in another report 
of over 3600 newly diagnosed patients who were recruited for the UKPDS [21] . The 
rate of microalbuminuria was significantly higher in the 39 percent of patients with 
hypertension (24 versus 14 percent in those without hypertension).  
The rate of microalbuminuria at the time of diagnosis of type 2 diabetes may 
be higher in older patients. This was illustrated in a cross-sectional population study  
in Finland (age 65 to 74 versus a mean of 52 years in the previous two studies) [22] 
.Microalbuminuria was present in 44 percent and hypertension in 68 percent of these 
patients; these values were significantly higher than in the subjects who did not 
develop diabetes. 
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There are at least two possible explanations for the presence of 
microalbuminuria at the time of diagnosis of type 2 diabetes: the patients had 
previously undiagnosed diabetes or some other disease (eg, benign 
nephrosclerosis) was responsible for the microalbuminuria. 
 
Progression to macroalbuminuria —  
As noted above, macroalbuminuria (also called overt proteinuria, clinical renal 
disease, or dipstick positive proteinuria) is defined as albumin excretion greater than 
300 mg/day or 20 µg/min or a urine albumin-to-creatinine ratio greater than 300 mg/g 
of creatinine or, using standard units, 34 mg/mmol of creatinine. 
Among the approximately 5100 patients (81 percent Caucasian) with newly 
diagnosed type 2 diabetes in the UKPDS described in the preceding section, the 
prevalence of macroalbuminuria was 5.3 percent at 10 years after diagnosis, 
compared to 25 percent for microalbuminuria [18] . The rate of progression from 
microalbuminuria to macroalbuminuria was 2.8 percent per year, which is similar to 
the 20 to 40 percent rate within a 10-year period noted in other studies of mostly 
Caucasian patients [4,23,24]  
In the systematic review cited above, patients with microalbuminuria had a 
significantly higher risk than those with normoalbuminuria of progressing to 
macroalbuminuria (relative risk 7.5, 95% CI 5.2-10.9) [16] . 
Other risk factors contributing to progression to macroalbuminuria include 
higher baseline levels of albuminuria, worse glycemic control as estimated from the 
hemoglobin A1c concentration, higher blood pressure, and cigarette smoking [23-25] 
. 
Ethnicity may also be important as four- to five-year rates of progression to 
macroalbuminuria as high as 37 to 42 percent have been described in Pima Indians 
and Israeli patients [26,27] . In older patients, other causes for proteinuria (such as 
benign nephrosclerosis) that might progress more slowly than diabetic nephropathy 
could have accounted for the lower rate of progression to macroalbuminuria. 
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Macroalbuminuria in patients with type 2 diabetes is typically associated with 
a progressive reduction in glomerular filtration rate (GFR). In the Pima Indian study, 
for example, the initial mean GFR was 143 mL/min in patients with newly diagnosed 
diabetes, 155 mL/min in those with microalbuminuria, and 124 mL/min in those with 
macroalbuminuria [26] . During four-year follow-up, the GFR increased by 18 percent 
in the patients with newly diagnosed diabetes, decreased by 3 percent in those with 
microalbuminuria, and decreased by 35 percent in those with macroalbuminuria. 
Microalbuminuria is unlikely to be a marker for susceptibility to the development of 
clinical nephropathy bur it is more likely to be a sign of early disease. This 
interpretation has been recently corroborated by the finding that patients with 
persistent microalbuminuria have more severe histological lesions than do patients 
with normal AER. 
 
MICROALBUMINURIA AND CARDIOVASCULAR DISEASE. 
Multiple studies in different patient populations have suggested that, in 
addition to its relation to renal disease, microalbuminuria is an important risk factor 
for cardiovascular disease and early cardiovascular mortality in patients with and 
without diabetes and/or hypertension. 
Clinical trials — HOPE (Heart Outcomes Prevention Evaluation) trial, the 
presence of microalbuminuria was associated with an increased relative risk of the 
primary aggregate end point (myocardial infarction (MI), stroke, or cardiovascular 
death) in those with and without diabetes (1.97 and 1.61, respectively) [12] . The risk 
of an adverse cardiovascular event increased progressively with increasing absolute 
levels of microalbuminuria.  
                             LIFE trial of patients with hypertension and electrocardiographic 
evidence of left ventricular hypertrophy, For every 10-fold increase in the albumin-to-
creatinine ratio, the risk of the composite end-point of cardiovascular death, MI, or 
stroke increased by 57 percent and the risk of cardiovascular death by 98 percent 
among nondiabetics. The respective increases in risk for diabetics were 39 and 47 
percent. A subsequent analysis of this trial showed that the risk of the composite 
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end-point of cardiovascular death, MI, or stroke was reduced among participants 
who had a substantial reduction in microalbuminuria at the one-year follow-up [32] . 
Population-based studies — have identified microalbuminuria as a significant 
predictor of cardiovascular risk [14,15,33] . In PREVEND study, urinary albumin 
excretion was measured in a general population sample of 40,548 participants who 
were followed for a median of 2.6 years [14] . When adjusted for age and sex, there 
was a graded increase in the relative risk of cardiovascular mortality of 1.35 for each 
doubling of urinary albumin excretion.  
The mortality risk in postmenopausal women was evaluated in a population-
based cohort study of 12,239 postmenopausal women [15] . Cardiovascular mortality 
was increased in those in the highest quintile of urinary albumin excretion (>21 mg/g 
creatinine [>2.41 mg/mmol]) compared to women without detectable albuminuria 
(13.2 versus 2.6 per 1000 years, age-adjusted rate ratio 4.4) [15] . This relationship 
was independent of diabetes and hypertension. 
Low-grade microalbuminuria —  Low levels of microalbuminuria, well under 
the above definitions (≥ 30 mg/day [20 µg/min] or urine albumin-to-creatinine ratio ≥ 
30 mg/g), are associated with an increase in cardiovascular risk that is additive to 
conventional risk factors [16,17,34-37] . In the Third Copenhagen Heart Study, 2726 
patients underwent a urine collection for measurement of albumin and were followed 
for the development of coronary heart disease or death [16] . The adjusted relative 
risk for coronary heart disease and mortality were 2.0 and 1.9, after adjustment for 
other risk factors.  
 Framingham Heart Study of 1568 nonhypertensive, nondiabetic men and 
women (mean age 55) [34] . The increase in risk remained significant in participants 
with a low or intermediate pretest probability of cardiovascular disease.. 
ST and T wave changes — The presence of microalbuminuria also enhances 
the predictive value of ST and T wave changes for cardiovascular disease. This was 
illustrated in  population-based PREVEND study [18] . Among 7330 subjects, 1244 
had ST-T changes; 885 had microalbuminuria. At a median follow-up of six years, 
the patients with both ST-T changes and microalbuminuria compared to those with 
ST-T changes alone had marked increases in the incidence of all-cause mortality 
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(7.2 versus 1.1 percent) and cardiovascular mortality (2.7 versus 0.5 percent). 
Microalbuminuria had a greater impact on the risk of all-cause mortality than 
hypertension, hypercholesterolemia, cigarette smoking, obesity, or diabetes mellitus.  
Possible mechanisms — How microalbuminuria is associated with 
cardiovascular disease is not well understood. Microalbuminuria in nondiabetics 
appears to be a signal from the kidney that the vasculature, particularly the 
endothelium, is not functioning normally. As examples: Vasodilation in response to 
certain stimuli is relatively reduced in older "normal individuals" with 
microalbuminuria compared to those without microalbuminuria [38] . Among 
nondiabetic patients with essential hypertension, those with microalbuminuria had 
higher plasma levels of von Willebrand factor (vWf) antigen than patients with normal 
albumin excretion [39] ; furthermore, individual vWf and albumin excretion values 
were significantly correlated. vWf has been associated with occlusive thrombosis; 
thus, the increased plasma vWf levels might directly contribute to the enhanced 
cardiovascular risk.  
 
Endothelial dysfunction is also present in diabetic patients [20] and the degree 
of coronary endothelial dysfunction appears to be greater in patients with 
microalbuminuria [40] . One important factor may be hyperglycemia-induced 
alterations in extracellular matrix, such as decreased density of heparan sulfate 
proteoglycans. This abnormality can lead to increased microvascular permeability, 
resulting in microalbuminuria at the glomerulus and perhaps increased lipoprotein 
deposition in peripheral vessels. in the Diabetes Control and Complications Trial, 
progressive increases in albuminuria were associated with elevations in 
proatherogenic intermediate-density lipoprotein and small dense LDL particles [41] .  
Microalbuminuria, the fifth pillar of syndrome X: 
Reavon in a seminar article has proposed that insulin resistance /hyperinsulinemia 
forms the common denominator between conventional cardiovascular risk factors 
and the development of atherosclerosis. Thus individual risk factors such as 
hypertension, obesity, hyperlipidemia and glucose intolerance, which commonly 
aggregate, simply represent the “rainbow colors” of a clinical syndrome 
33 
 
characterised by an underlying state of insulin resistance and a devastating 
cardiovascular outcome in what Reavon referred to collectively as syndrome X. 
Interestingly there is now evidence to promote microalbuminuria as a distinct and 
independent facet of this disorder. Investigating theinfluence of microalbuminuria and 
hypertension on insulin resistance in Type II DM patients, Group et al reported that 
glucose metabolism, as measured during insulin clamp technique, was impaired in 
normotensive Type II DM patients with microalbuminuria compared with 
normotensive normoalbuminuric patients. The defect in insulin action wasshown to 
correlate with urinary albumin excretion. Furthermore, diabetic subjects with a 
combination of hypertension and microalbuminuria had a greater reduction in insulin 
mediated glucose disposal and widespread disturbances in lipid metabolism. 
Perhaps the most surprising finding of these studies was the observation that insulin- 
stimulated glucose disposal was remarkably normal in normotensive Type II DM 
patients who did not have microalbuminuria54. A similar conclusion has also been 
reached by Nosadini and Zambon et al who showed that insulin sensitivity was not 
compromised in healthy Type II DM patients unless either microalbuminuria or 
hypertension or both existed55. The relationship between insulin resistance and 
albuminuria in Type II DM subjects was alsoconfirmed by Niskanen and Laaksa who 
showed that insulin mediated glucose uptake determined during euglycemic clamp 
study was significantly lower in Microalbuminuric when compared with 
normoalbuminuric patients, independent of the confounding effectof hypertension. 
Thus, the association between insulin resistance and microalbuminuria in Type II DM 
as revealed by the findings of these studies raises the interesting question of 
whether the two phenomena might in some way be causally related. However, the 
presence of microalbuminuria in Type II DM has not been marked by a reduction in 
insulin sensitivity in all of the studies thus far reported. For the present, therefore the 
mechanism relating insulin resistance/hyperinsulinemia to albuminuria remains 
largely speculative56. 
Finally, two recent reports have shed further insight into the significance of 
microalbuminuria in Type II DM. Haffner et al in a cross-sectional study, and 
Mykannen et al in a prospective study, have reported that microalbuminuria in non-
diabetic individualsmay precede and even predict the onset of Type II DM. Moreover, 
microalbuminric subjects who remained glucose tolerant after 3.5 years of follow-up 
still demonstrated multiple cardiovascular abnormalities, including elevated blood 
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pressure, high triglyceridesconcentration, high insulin concentration, and low HDL 
cholesterol concentration, i.e. a cardiovascular risk profile akin to that observed in 
prediabetic individuals. Microalbuminuria may be regarded as a prominent feature of 
the prediabetic state. The above findings therefore provide probably the most 
damaging evidence against microalbuminuria as a serious phenomenon in the 
evolution of Type II DM and atherosclerotic disease57, 58. 
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TREATMENT OF INCIPIENT NEPHROPATHY 
 
Microalbuminuria indicates early stage of development of diabetic 
nephropathy and also a marker of increased mortality from cardiovascular risk 
factors. Microalbuminuria is also associated with other microvascular and 
macrovascular complications of diabetes. It is a warning sign for the patient, which 
should not be neglected. Progress of microalbuminuria to macroalbuminuria or overt 
nephropathy can 
be reversed or delayed by intervention at this stage. 
 
The strategies for treatment at this stage include1, 5, 7, 8, 61: 
 
1) Optimum glycaemic control-diet, intensified insulin treatment, oral hypoglycemic 
agents 
2) Blood pressure control and ACE inhibitors 
3) Dietary treatment 
4) Newer treatment modalities which are under study 
 Aldolase reductase inhibitors 
 Glycosaminoglycans 
5) Correction of cardiovascular risk factors and other diabetic complications. 
 Stopping of cigarette smoking 
 Correction of dyslipidemia 
 
Optimum glycaemic control 
In patients with Type I DM with microalbuminuria, strict metabolic control by 
continuous subcutaneous insulin infusion has been effective in reducing AER. 
Similar reduction in AER is seen after multiple injection therapy, provided that similar 
levels of blood glucose control are achieved, a finding suggesting that it is the 
attained blood glucose control concentration rather than the modality of treatment 
that matters62 
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Blood pressure control: 
ACE inhibitors/ARBs — Angiotensin converting enzyme (ACE) inhibitors and 
angiotensin II receptor blockers (ARBs) have similar efficacy in type 2 diabetic 
patients with microalbuminuria. The only randomized comparative trial (DETAIL) of 
these agents in type 2 diabetic patients compared enalapril to the ARB telmisartan in 
250 patients with early nephropathy as defined by albuminuria (82 percent 
microalbuminuria and 18 percent macroalbuminuria to a maximum of 1.4 g/day) and 
a baseline GFR (measured isotopically) of approximately 93 mL/min per 1.73 m2 
[33] . A greater fall in GFR of at least 10.0 mL/min per 1.73 m2 at five years was 
predefined as suggesting a clinically significant difference between the two treatment 
groups. 
At five years, there was a smaller decline in GFR with enalapril that was not 
significant (14.9 versus 17.9 mL/min per 1.73 m2 with telmisartan). Both groups had 
similar rates or findings for the secondary end points, which included annual 
changes in the GFR, blood pressure, serum creatinine concentration, urinary 
albumin excretion, end-stage kidney disease, cardiovascular events, and mortality.  
Preferential renoprotective benefits with ACE inhibitors or ARBs compared to 
that observed with placebo have also been noted in a number of trials [27,34-38] . 
The potential magnitude of benefit can be illustrated by the results of the RENAAL 
trial in which 590 hypertensive patients with type 2 diabetes and microalbuminuria 
were randomly assigned to either irbesartan (150 or 300 mg/day) or placebo and 
then followed for two years [34] . 
The primary end point was the time from baseline to first detection of overt 
nephropathy (urine albumin excretion >200 µg/min [macroalbuminuria] and at least a 
30 percent increase from baseline on two consecutive visits). This end point was 
significantly more common in the placebo group compared to irbesartan (14.9 versus 
9.7 and 5.2 percent with 150 and 300 mg of irbesartan). This benefit was not related 
to differences in blood pressure, although the systolic blood pressure was 3 mmHg 
lower with 300 mg irbesartan than with placebo or 150 mg irbesartan (141 versus 
144 mmHg), a difference that was statistically significant. 
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In patients with type 2 diabetes and microalbuminuria, either an ACE inhibitor 
or an ARB is recommended to slow or prevent progression to macroalbuminuria and 
overt diabetic nephropathy. The renal goal of ACE inhibitor therapy is a modest 
reduction in urine albumin excretion. 
Calcium channel blockers — Calcium channel blockers have less 
antiproteinuric effect than ACE inhibitors or ARBs, and the antiproteinuric effect is 
primarily seen with diltiazem and verapamil, not the dihydropyridines.  
The difference between these drug classes was evaluated in the MARVAL 
trial in which 332 patients with type 2 diabetes and microalbuminuria were randomly 
assigned to valsartan or amlodipine [39] . Albumin excretion was reduced by 92 
percent with valsartan compared to 56 percent with amlodipine, a difference that was 
highly significant.  
Dietary and Behavioural modification: 
Reductions of dietary protein by approximately 50% has been shown to 
reduce the fractional clearance of albumin in patients with microalbuminuria, and to 
lower GFR in patents with hyperfiltration, independently of changes in glucose 
control and pressure. 
Diets restricted 0.5-0.6gm of protein /kg body weight per day is ideal and does 
not have long-term detrimental effect on nutritional status of an individual. Cessation 
of cigarette smoking should always be advised in a patient with microalbuminuria61. 
Other treatment modalities: 
Aldolase reductase inhibitors, which have been studied in a few studies, show 
reduction in GFR and decreases in AER in Type II DM patients who had either a 
normal AER or microalbuminuria. But study in subjects with Type II DM with 
microalbuminuria it failed to show any effects on renal function. Further studies are 
needed to confirm the finding. 
Recent observation suggests that oral administration sulodexide (a naturally 
occurring glycosaminoglycan) extracted from pig intestinal mucosa, containing a fast 
moving heparan like fraction (80%) and a dermatan sulphate fraction (20%) along 
with ACE inhibitors seems to retard progression from incipient to overt nephropathy 
in Type II DM patients. Mechanism is possibly by restoring glomerular basement 
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membrane charge and size selectivity to albumin molecules as well as reducing 
glomerular capillary pressure. Further studies are needed to confirm this finding68. 
 
Correlation of cardiovascular risk factors and other complications: 
A detailed cardiovascular examination is necessary early in the course of 
diabetic nephropathy. Hypertension must be treated energetically. Left ventricular 
hypertrophy and function should be assessed echocardiographically at the stage of 
microalbuminuria and thereafter every 6 –12 months. Effective antihypertensive 
therapy can reverse leftventricular hypertrophy. In addition cardiac assessment 
should includeelectrocardiography, stress testing, coronary angiography and Holter 
monitoring is indicated whenever needed. Ischemic heart disease should be treated 
aggressively. 
Peripheral vascular disease must be assessed and treated as necessary. 
Doppler flow studies and arteriography may be useful to assess the severity of the 
disease69, 70. 
Microalbuminuria is frequently associated with hyperlipidemia and lipid profile 
is an essential investigation and dyslipidemia should be treated71. 
Testing vibration perception threshold and thermal discrimination may identify 
the risk of neuropathic ulceration. The test should be repeated regularly as sensation 
may become impaired later, during the course of nephropathy. Autonomic 
dysfunction is very common in nephropathic patients. The important manifestations 
are postural hypotension and incomplete bladder emptying which predisposes to 
urinary tract infection72. 
Microalbuminuria is frequently associated with retinopathy. Retinopathy 
almost always accompanies diabetic nephropathy. Early and regular ophthalmic 
review and prompt treatment is necessary to prevent blindness73, 74. 
 
PRIMARY PREVENTION —  
In addition to treating microalbuminuria to prevent progressive disease, 
clinical trials have also demonstrated efficacy of ACE inhibitors and ARBs and of 
glycemic control for the primary prevention of microalbuminuria and subsequent 
overt nephropathy in patients with type 2 diabetes. 
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Glycemic control — As noted above, worse glycemic control is a risk factor for 
both the development of microalbuminuria and for progression to macroalbuminuria 
in patients with type 2 diabetes. Strict glycemic control is recommended in all 
patients because of its beneficial effects on the microvascular complications. 
The UKPDS evaluated the importance of strict glycemic control in 3867 
patients with newly diagnosed type 2 diabetes [43] . The patients were randomly 
assigned to intensive or conventional therapy. Over 10 years, the average 
hemoglobin A1C value was 7.0 percent in the intensive therapy group, compared to 
7.9 percent in the conventional therapy group (an 11 percent reduction). 
 ADVANCE trial in which 11,140 patients with type 2 diabetes (mean duration 
eight years) were randomly assigned to intensive therapy to achieve a hemoglobin 
A1c below 6.5 percent or to standard therapy [17] . At a median follow-up of five 
years, the intensive and standard groups achieved mean hemoglobin A1c values of 
6.5 and 7.3 percent, respectively.  
ACE inhibitors or ARBs — There have been variable results related to the 
efficacy of ACE inhibitors [36,44-49] or ARBs [50] for the primary prevention of 
nephropathy in clinical trials of patients with type 2 diabetes 
Among normotensive patients, the rate of progression to microalbuminuria 
was significantly lower with enalapril compared to placebo [45,46] and, in the ABCD 
trial, enalapril was equivalent to nisoldipine [46] . Among hypertensive patients, the 
rate of progression to microalbuminuria was similar with captopril and atenolol in the 
United Kingdom Prospective Diabetes Study [47] , significantly lower with trandolapril 
compared to verapamil  
A meta-analysis and the BENEDICT trial illustrate the magnitude of these 
effectsACE inhibitors significantly reduced the progression to microalbuminuria or 
macroalbuminuria compared to placebo and to calcium channel blockers. The 
benefit was similar in patients with and without hypertension. Based upon these 
observations, administration of an ACE inhibitor is recommended in hypertensive 
normoalbuminuric patients with type 2 diabetes. Although ARBs are likely to provide 
similar benefits, this has not yet been proven for these agents. 
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There is insufficient evidence to recommend ACE inhibitor therapy for primary 
prevention in patients with type 2 diabetes who are normotensive. These patients 
should be screened yearly for microalbuminuria and an ACE inhibitor initiated if 
persistent microalbuminuria is documented. 
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METHODS OF MEASURING MICROALBUMINURIA 
 
Small concentration of albumin in the urine can be measured qualitatively by several 
methods.Radioimmunoassay was the first and most widely used method. Various 
methods to determine microalbuminuria are given in the table59. 
 
 
METHOD 
 
SENSITIVITY 
 
TIME OF ASSAY 
Single radio immune 
diffusion(Manini1965) 
 
1.25 mg/ml 
 
1 day 
Electroimmuno assay (Laurel1966) 5 mg/l 4-6 hrs 
Immunoturbidimetric assay 
(Teppor1982) 
 
5 mg/l 
 
20-30 min 
Radio immuno assay (Keen and 
Chlouvervakis, 1963) 
 
6.2 mcg/l 
 
1-2 days 
ELISA (Filding 1983) 250 mcg/l 12-18 min 
Fluorescent immuno assay (Chavers 
1984) 
 
500 mcg/l 
 
4-6 hrs 
Latex agglutinates immuno 
nephelometry(Vasquez 1984) 
 
750 mcg/l 
 
6 hrs 
Immuno chemical semi quantitative 
dipstic (MICRAL) 
20-300 mg/l 5 sec – 5 min 
 
In our study we have used Micral test for estimation of microalbuminuria. 
Micral test (Boehringer Mannheim, Germany) is dipstick method of estimation of 
microalbuminuria. Test principle is immunochemical in nature. Sensitivity of Micral 
test was 93% and its specificity was 93% when compared to radioimmunoassay in a 
study by Gilbert PE et al60. Micral test has also been compared with 
immunoturbidimetricassay and radioimmunoassay methods. In all studies Micral test 
is comparable in sensitivity and specificity to the other methods of estimation of 
microalbuminuria. 
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MATERIALS AND METHODS 
 
One  hundred patients of Type II DMadmitted  to PSGIMS & R were studied. The 
patients were taken from both IP and OP of the hospital, based on random selection. 
Patients were considered to be diabetic based on WHO (2) criteria for diagnosis of 
diabetes mellitus 
which is : - 
1) Symptoms of diabetes mellitus plus a random glucose concentration >200 
(11.1mmol/l). The classic symptoms of diabetes mellitus include polyuria, polydipsia 
and unexplained weight loss 
OR 
2) Fasting blood glucose >126 mg/dl (7.0mmol/l). Fasting is defined as no caloric 
intake for at least 8 hours 
OR 
3) 2 hour post prandial glucose > 200mg/dl (11.1 mmol/l). Among diabetics, the 
above criteria were considered to include the patients for the study. 
OR 
4)HbA1C> 6.5 
 
Inclusion criteria for case selection: 
1) Urine sugar – positive 
2) Fasting blood sugar > 126 mg/dl 
 
Exclusion criteria for case selection: 
1) Patients with macroalbuminuria 
2) Patients with congestive cardiac failure, urinary tract infection. 
3) Ketonuria 
4) Pregnant patients 
5) Patients with overt diabetic nephropathy 
The selected patients were studied in detail with history and physical examination 
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History: 
 Patient’s characteristics age, sex, age of onset and duration of diabetes. 
 All details regarding the presenting complaints were noted. 
 Total duration of diabetes, the drugs the patient was taking and the dosages were 
noted. The regularity of the treatment taken by the patients was also noted. The 
family history regarding diabetes was taken. 
 Personal history regarding smoking, alcohol consumption, bowel and bladder 
habits and drug intake were noted. 
 
A complete clinical examinationwas carried out in each patient with 
particular reference to the complications of diabetes like retinopathy, neuropathy, 
diabetic foot and ischemic heart disease. 
 
Height and weightwere measured in all cases and body mass index (BMI) was 
calculated by weight in kg / height in m2  
Hypertension was said to be present when there was a history of 
hypertension or the systolic blood pressure was recorded greater than 160mm of hg 
and/or diastolic pressure greater than 90 mm of hg on 3 consecutive occasions. 
Ischemic heart disease was recorded to be present in the presence of suggestive 
history of angina or myocardial 
infarction with electrocardiographic evidence.  
Peripheral neuropathy was judged to be present if there was historical 
evidence of neuropathic pain, numbness or tingling sensation in the extremities and 
or absence of ankle jerks along with diminished vibratory threshold or pin prick 
sensation in hands or feet on examination. 
Fundus examination was done in all patients for evidence of diabetic 
retinopathy. Retinopathy was said to be present when there was evidence of 
microaneurysm, soft or hard exudates and hemorrhages.  Neovascularity was 
considered as evidence for proliferative retinopathy. 
Peripheral vascular disease was considered to be present with history of 
amputations and /or absent of one or more peripheral pulses and /or presence of 
gangrenous foot. 
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The following investigations were done in all the patients. 
 Microalbuminuria was estimated by Micral test in all the cases. 
 Fasting Blood sugar and Postprandial blood sugar 
 Glycosylated hemoglobin 
 Blood urea and serum creatinine 
 Fasting lipid profile 
 Urine routine and culture 
 Electrocardiogram 
 Ultrasonography of the abdomen, echocardiogram and chest x-ray were done in 
selected cases only. 
 
Estimation of Microalbuminuria by Micral test: All patients having overt 
macroalbuminuria detected by albustic were excluded from study. Micral test, a 
immunological rapid dip stick semi qualitative technique for detection of 
microalbuminuria, was used for estimation of microalbuminuria. 
 
Micral test components: 1 test strip contains monoclonal antibodies against human 
albumin (immunoglobulin G) labeled with colloid gold 2.2mg, fixed albumin 7.7 mg 
 
TEST PRINCIPLE: 
There is a serial arrangement of several reagent pads, which are in fluid 
communication by a reaction controlling chromatographic process. This step 
combines one step handling with a complex chemistry. The single reaction steps are 
as follows: 
 Urine of the sample is transported through the wick fleece to the buffer fleece, 
where acidic urine is adjusted to proper pH. Upon entering the conjugate fleece the 
antigen – antibody reaction takes place Albumin of the sample is specifically bound 
to a soluble conjugate of antibodies and marker enzyme resulting in an antigen – 
conjugate complex 
 The excess antibodies are bound to immobilized albumin on the capture matrix and 
removed from the sample in this way. 
 Only the complex of conjugate with sample-albumin reaches the substrate pad. 
Here the color reaction takes place, the marker enzyme B-Galactosidase cleaves off 
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the purple dye chlorophenol red from the Yellow substrate (chlorophenol red 
galactoside) in a kinetic reaction. The intensity of the color produced is proportional 
to the albumin concentration in the urine. 
SPECIMEN COLLECTION: 
All patients were afebrile during the course of collection of urine and were 
kept at rest during the collection of urine. Urine of the patient was first tested for 
albumin by albustix method. Patients who were negative for albumin by the albustix 
method were only included in this study. 
First morning mid stream urine sample that was collected in a sterile container 
was used for determining microalbuminuria. Test strip was immersed in urine such 
that fluid level was between the two black bars provided on the strips. Strip was 
withdrawn after 5 seconds. Strip was placed horizontally across the urine vessel and 
color change inthe test zone was compared with color scale after one minute. 
Sensitivity of the kit is 0.4ng/ml and measuring range is 0.8 to 10ng/ml. 
 
Microalbuminuria was graded as follows: 
Mild (20-50mg/L)- + 
Moderate (50-100mg/L) - ++ 
Severe (100-300mg/L)- +++ 
Depending on the color change in the strip. 
 
Severity of diabetes was graded based on the HbA1c levels, as follows: 
Mild - <7.0% 
Moderate- 7.0% to 7.5% 
Severe- > 7.5% 
Blood urea, serum creatinine and lipid profile were estimated in all cases. 
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STATISTICAL METHODS 75, 76 
 
Chi-square and Fisher Exact test have been used to find the significance of 
proportion of incidence of microalbuminuria between various levels of study 
parameters namely BMI, Age, Duration of DM, GHB %, abnormal lipid profile and 
complications etc. The Odds ratio has been used to find the strength of relationship 
between the incidence of microalbuminuria and other study parameters. Student t 
test has been used to find the significance of mean levels of lab parameters between 
the presence and absence of microalbuminuria 
 
Statistical software:The Statistical software namely SPSS 11.0 and Systat 8.0 were 
used for the analysis of the data and Microsoft word and Excel have been used to 
generate graphs, tables etc. 
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RESULTS AND  STATISTICALANALYSIS 
 
 
 
 
Study design 
 
 
A Prospective clinical study consisting of 100 Type 2 DM patients is undertaken to 
investigate the pattern and magnitude of microalbuminuria and its relationship with 
microvascular and macrovascular complications of Type 2 DM 
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Table 1 shows the age and sex distribution of patients 
 
Table1: Age and sex distribution 
 
 
16 patients were in the age group between 30 and 40 years, among whom 9 
were maleand 7 were female patients. 23 patients were in the age group between 41 
and 50 years,among whom 14 were male and 9 were female patients. 31 patients 
were in the age groupbetween 51 and 60 years, among whom 15 were male and 16 
were female patients. 20patients were in the age group between 61 and 70 years, 
among whom 14 were male and6 were female patients. 10 patients were in the age 
group greater than 70 years, amongwhom 5 were male and 5 were female patients. 
The mean age of male patients in thestudy was 54.82 + 12.38 years and that of the 
female patients was 54.82 + 11.08 years.The mean age of detection of diabetes 
mellitus among the male patients was 48.84+ 10.11years and in the patients was 
48.75 + 8.68 years. 
The mean age between male and female is not statistically significant 
withp=0.964 and the mean age of detection of DM is not statistically significant with 
P=0.965 
 
Age in years Male Female Total 
No % No % 
30-40 9 15.7 7 16.28 16 
41-50 14 24.56 9 20.93 23 
51-60 15 20.32 16 37.21 31 
61-70 14 24.56 6 13.95 20 
>70 5 8.77 5 11.63 10 
Total  57 100 43 100 100 
Mean age 
 SD 
54.82+/-12.38  54.82+/-11.08 54.87+/-11.59 
Mean age of 
detection of DM 
48.84+/-10.11  48.75 +/- 8.68  48.79 +/-9.27 
P value  
 
Mean age between male and female = 0.965 
Mean age of detection of diabetes= 0.964 
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Table 2 shows the duration of diabetes mellitus since diagnosis 
 
Table2: Duration of diabetes mellitus since diagnosis 
Duration of DM MALE 
(n=57) 
FEMALE 
(n=43) 
Total 
 (n=100) 
N0 % NO % 
<5 35 61.4 24 55.81 59 
5.1-10 12 21.05 11 25.58 23 
10.1-15 5 8.77 6 13.95 11 
>15 5 8.77 2 4.65 7 
Mean duration of 
DM  SD 
6.194.31 6.114.75 6.144.54 
P value 0.930 
 
 
 
A total of 59 patients had duration of diabetes since diagnosis less than 5 
yearsamong which 35 were male and 24 female patients. 23 patients had duration of 
diabetessince diagnosis between 5 years and 10 years among which 12 were male 
and 11 werefemale patients. 11 patients had duration of diabetes since diagnosis 
between 10 years and15 years among which 5 were male and 6 were female 
patients. 7 patients had duration ofdiabetes since diagnosis greater than 15 years 
among which 5 were male and 2 werefemale patients. The mean duration of 
diabetes since diagnosis was 6.19 +4.31 yearsamong the male patients and 
6.11+4.75 years among the female patients. The meanduration of DM is not 
statistically significant between male and female patients withp=0.930 
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FIGURE 2 
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Table 3 shows the number of patients with microalbuminuria in this study. 
 
 
Table3: Number of patients with Microalbuminuria 
 
 
 
There were 62 patients negative for microalbuminuria. 11 patients had 
microalbuminuria between 20 to 50 mg/l. 18 patients had microalbuminuria between 
50 to100 mg/l. finally 9 patients had microalbuminuria between 100 to 300 mg/l. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microalbuminuria 
 
Number 
(n=100) 
- 62 
+ 11 
++ 18 
+++ 9 
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Table 4 shows the number of patients on different treatment for diabetes mellitus 
 
Table4: Treatment 
 
 
4 patients were on treatment with Insulin and 84 patients were on treatment 
withoral hypoglycaemic agents whereas 12 patients were on both insulin and oral 
hypoglycaemic drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT NUMBER 
n =100 
INSULIN 4 
OHA 84 
INSULIN +OHA 12 
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Table 5 shows the association of age with microalbuminuria 
 
Table5: Association of Age with Microalbuminuria 
 
 
 
 
Among the 16 patients in the age group between 31 to 40 years 3 patients 
hadmicroalbuminuria. 23 patients were in the age group between 41 to 50 years 
amongwhom 5 patients had microalbuminuria. 31 patients were in the age group 
between 51 to60 years among whom 11 patients had microalbuminuria. 20 patients 
were in the agegroup between 61 to 70 years among whom 10 patients had 
microalbuminuria. 10 patientswere in the age group greater than 70 years among 
whom 9 patients hadmicroalbuminuria. 
 
Incidence of Microalbuminuria is 2.54 times more likely for the age group > 
50years of age as compared to the age group <50 years with 2=3.757, P=0.053 
 
 
 
 
 
 
 
 
 
 
AGE IN 
YEARS 
MICROALBUMINURIA 
- + ++ +++ TOTAL 
30-40 13 3 - - 16 
41-50 18 2 2 1 23 
51-60 20 4 7 - 31 
61-70 20 1 5 4 20 
>70 1 1 4 4 10 
TOTAL 62 11 18 9 100 
P VALUE Incidence of microalbuminuria is 2.54 times more 
likely for age group > 50 years P=0.053 
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Table 6 shows the association of the duration of diabetes since diagnosis with the 
incidence of microalbuminuria 
 
Table6: Association of Duration of DM since diagnosis with the incidence of 
Microalbuminuria 
 
 
 
 
 
 
 
 
 
 
The number patients with the duration of diabetes since detection less than 5 
years were 59 and among them 3 were positive for microalbuminuria. The number 
patients with the duration of diabetes since detection 5 years and 10 years were 23 
andamong them 10 were positive for microalbuminuria. The number patients with 
theduration of diabetes since detection 10 years and 15 years were 11 and among 
them 10were positive for microalbuminuria. All the patients i.e. 7 with duration more 
than 15years were positive for microalbuminuria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
DURATION 
OF DM 
MICROALBUMINURIA 
- + ++ +++ TOTAL 
<=5 56 2 1 - 59 
5.1-10.0 5 8 8 2 23 
10.1-15.0 1 1 8 1 11 
>15.0 - - 1 6 7 
P value P < 0.001 
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Table 7 shows the association of HbA1c with the incidence of microalbuminuria 
 
Table 7:Association of HbA1c with the incidence of Microalbuminuria 
 
 
 
 
 
 
 
 
  
22 patients had HbA1c values less than 6.5% and among them 6 were 
positive formicroalbuminuria. 22 patients had HbA1c values between 6.5% and 
7.0%, among them 5were positive for microalbuminuria. 16 patients had HbA1c 
values between 7.0% and7.5%, among them 4 were positive for microalbuminuria. 
40 patients had a HbA1c valuesmore than 7.5%, among them 23 were positive for 
microalbuminuria 
 
 
 
 
 
 
 
 
 
 
 
 
HbA1c 
 
Microalbuminuria 
(n=100) 
- + ++ +++ TOTAL 
<6.5 16 4 1 1 22 
6.5-7.0 17 2 2 1 22 
6.5-7.0 12 2 2 - 16 
>7.5 17 3 13 7 40 
P value  7.0%, p= 0.018 
 7.5%, p= 0.001 
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FIGURE 7 
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Table 8 shows the association of body mass index with microalbuminuria 
 
Table 8:Association of body mass index with the incidence of 
Microalbuminuria 
 
 
a Near significance * Significance at 5% ** Significance at 1% 
 
 
7 patients had a BMI less than 19kg/m2 and out of them 2 patients were 
positivefor microalbuminuria. 71 patients had a BMI between 19kg/m2 and 25 kg/m2 
and out ofthem 23 patients were positive for microalbuminuria. 22 patients had a BMI 
above 25kg/m2 and out of them 13 patients were positive for microalbuminuria. 
Incidence of Microalbuminuria is significantly associated & Positively with BMI>25 
and Negatively associated with BMI <25 kg/m2 with P<0.05 
 
 
 
 
 
 
 
 
 
 
 
Body mass 
index 
(Kg/m2) 
(n=100) 
Microalbuminuria 
 
 
- + ++ +++ TOTAL OR 
<19 5 - 1 1 7 0.63 
(P=0.706) 
19-25 48  3  14  6  71 0.44 
(P=0.071a 
>25 9 8 3 2 22 3.06 
(P=0.027*) 
P value P< 0.05 
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Table 9 shows the association of lipid parameters with the incidence of 
microalbuminuria 
 
Table 9: Association of Lipid Parameters with the incidence of 
Microalbuminuria 
 
 
 
30 patients had Total cholesterol greater than 200 mg/dl and among them 11 
patients were positive for microalbuminuria. 37 patients had Triglycerides greater 
than160 mg/dl and among them 16 patients were positive for microalbuminuria. 11 
patientshad LDL greater than 150 mg/dl and among them 5 patients were positive 
formicroalbuminuria. 33 patients had HDL lesser than 30 mg/dl and among them 16 
patientswere positive for microalbuminuria.Incidence of microalbuminuria is not 
significantly associated with the abnormallipid parameters, however, the incidence of 
microalbuminuria is 1.93 times more likelyfor the patients presented with HDL <30 
mg/dl. 
 
 
 
 
Body mass 
index 
(Kg/m2) 
(n=100) 
Microalbuminuria 
 
OR 
- + ++ +++ TOTAL 
T.Cholesterol 
(>200 mg/dl) 
20 4 3 3 30 1:0.65 
(P=0.359) 
Triglycerides 
(>160 mg/dl) 
21 6 7 3 37 1:1.42 
(P=0.408) 
LDL 
(>150 mg/dl) 
6 - 3 2 11 1:1.41 
(P=0.744) 
HDL 
(<30 mg/dl) 
17 3 8 5 33 1:1.41 
(P=0.744) 
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Table 10 shows the association of complications with the incidence of 
microalbuminuria 
 
Table 10:Association of Complications with the incidence of Microalbuminuria 
 
 
a Near significance * Significance at 5% ** Significance at 1% 
 
13 patients had retinopathy, among them 8 patients were positive for 
microalbuminuria. 39 patients had peripheral neuropathy, among them 21 patients 
werepositive for microalbuminuria. 8 patients had peripheral vascular disease, 
among them 4patients were positive for microalbuminuria. 21 patients had Ischemic 
heart Disease(IHD), among them 13 patients were positive for microalbuminuria. 23 
patients hadhypertension, among them 18 patients were positive for 
microalbuminuria. 22 patientshad a BMI above 25 kg/m2 and out of them 13 patients 
were positive for microalbuminuria 
 
 
 
 
 
Complications 
(n=100) 
Microalbuminuria 
 
OR 
- + ++ +++ TOTAL  
Retinopathy 5 1 5 2 13 1:3.04 
(P=0.073a) 
Peripheral 
Neuropathy 
18 5 10 6 39 1:3.02 
(P=0.009**) 
Peripheral 
vascular 
diseases 
4 - 2 2 8 1:1.71 
(P=0.474) 
Ischemic 
heart 
Disease (IHD) 
8 3 9 1 21 1:3.51 
(P=0.011*) 
Hypertension 5 - 13 5 23 1:10.26 
(P<0.001**) 
BMI 
(>25 kg/m2) 
9 8 3 2 22 1:3.06 
(P=0.027*) 
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Table 11 shows the mean pattern of laboratory parameters in the presence of 
Microalbuminuria 
 
Table 11: Mean Pattern of Lab parameters in the presence of 
Microalbuminuria 
 
a Near significance * Significance at 5% ** Significance at 1% 
 
The mean value of FBS in the presence of microalbuminuria was 194.44 ± 34.39 
mg/dland 172.39 ± 26.22 mg/dl in the absence of microalbuminuria. The mean value 
of PPBSin the presence of microalbuminuria was 273.92 ± 48.49 mg/dl and 244.97 
±30.19 mg/dlin the absence of microalbuminuria. The mean value of GHB% in the 
presence ofmicroalbuminuria was 8.06 % ± 1.41 % and 7.06% ± 0.81% in the 
absence ofmicroalbuminuria. The mean value blood urea of in the presence of 
microalbuminuriawas 29.95 ± 6.81 mg/dl and 29.19 ± 6.02 mg/dl in the absence of 
microalbuminuria. Themean value serum creatinine of in the presence of 
microalbuminuria was 1.05 ±0.19mg/dl and 1.04 ±0.16 mg/dl in the absence of 
Lab parameters Microalbuminuria Lab 
parameters (Mean ±SD) 
 
Significance by 
student t test 
Absent  Present 
FBS mg/dl 172.39  
± 26.22 
194.44 ± 
34.39 
P<0.001** 
PPBS mg/dl 244.97 
±30.19  
273.92 ± 
48.49 
P<0.001** 
GHB % 7.06 ± 0.81  8.06 ±1.41 P<0.001** 
Blood Urea mg/dl 29.19 ±6.02  29.95 ± 6.81 P=0.555 
S. Creatinine mg/dl 1.04 ± 0.16  1.05±0.19 P=0.915 
T.Cholesterol mg/dl 188.09 
±29.61  
188.74 ± 
38.75 
P=0.926 
TGL mg/dl 153.31 
±60.06  
164.61 ± 
63.52 
P=0.374 
LDL mg/dl 125.97±21.75  125.58 ± 
26.82 
P=0.937 
HDL mg/dl 31.46 ± 3.52  30.23 ± 3.40 P=0.089a 
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microalbuminuria. The mean value oftotal cholesterol in the presence of 
microalbuminuria was 188.74 ± 38.75mg/dl and188.09 ± 29.61 mg/dl in the absence 
of microalbuminuria.  
 
 
The mean value oftriglycerides in the presence of microalbuminuria was 
164.61 ± 63.52 mg/dl and 153.31 ±60.06 mg/dl in the absence of microalbuminuria. 
The mean value of LDL cholesterol inthe presence of microalbuminuria was 125.58 ± 
26.82 mg/dl and 125.97 ± 21.75 mg/dl inthe absence of microalbuminuria. The mean 
value of HDL cholesterol in the presence ofmicroalbuminuria was 30.23 ±3.40 mg/dl 
and 31.46 ±3.52 mg/dl in the absence ofmicroalbuminuria. 
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DISCUSSION 
 
Type 2 diabetes mellitus is being increasingly recognized as a disease, which 
is characterised by dysfunction of the endothelium. Endothelial dysfunction occurs in 
a generalized and widespread manner in diabetic subjects. The severity of the 
dysfunction is directly proportional to the age of the patient and duration of the 
diabetes. The clinical markers of the generalized endothelial dysfunction becomes 
manifest in several forms. Microalbuminuria marks the onset of endothelial 
dysfunction related to the kidney. Since its original description by Mogensen, the 
estimation of microalbuminuria is made easy and practical.  Microalbuminuria serves 
as a warning for imminent nephropathy. But its true value is that it heralds 
generalized endothelial dysfunction. Thus diabetic subjects with microalbuminuria 
not only have ongoing progressive nephropathy but are also likely to have 
retinopathy, nephropathy and cardiovascular problems including coronary artery 
disease and hypertension. An effort has been made in this study to highlight this 
issue. Even among randomly selected patients an incidence of 38% for 
microalbuminuria is evident. Among various other studies the prevalence of 
microalbuminuria ranges from 25% to 35% 78, 79, 80, 81. A slight increase in the 
percentage of microalbuminuria in our 
study can be attributed to several factors such as, large number of  elderly patients, 
longer duration of diabetes and poor glycemic control. 
It is very well recognized that microalbuminuria occurs more commonly in diabetic 
subjects who are more than 50 years of age. In our study microalbuminuria  tended 
to be 2.54 times more common in the age group of above 50 years as compared to 
the age group of less than 50 years. There are many reasons for this phenomenon. 
Firstly deterioration in the -cell function, which occurs parripassu with increasing 
duration of diabetes, is likely to contribute to worsening glycemic control. Poor values 
of HbA1c are known to be associated with increasing incidence of microalbuminuria. 
In our study only 11 out of 44 patients who had a normal HbA1c (< 7.0%) manifested  
Microalbuminuria, whereas with HbA1c values more than 7, 27 out of 56 (nearly 
50%) had microalbuminuria. It is seen from the above result that even small 
increments of HbA1c more than 7.0% result in almost doubling of the incidence of 
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microalbuminuria. It is also interesting to note that when HbA1c rises above 7.0%, 22 
out of 27 patients tended to have more than 50mg/l and 7 out of 27 had 
microalbuminuria touching 300mg/l. 
Although this is a cross sectional study, these findings raise concern regarding the 
blatant association between poor glycemic control and microalbuminuria in a rural 
setting. 
This study has also brought out a significant association of microalbuminuria 
with body mass index of more than 25kg/m2. Of the 22 patients with BMI of more 
than 25, 13 had microalbuminuria (52%). Similar findings have been brought forth by 
other studies79, 80, 81. The possible explanation for this could be 
1. Increasing body mass index is a reflection of insulin resistance which inturn leads 
to endothelial dysfunction and microalbuminuria. 
2. Associated hypertension may also be responsible for microalbuminuria. 
3. Poor glycemic control which inturn is an outcome of insulin resistance is also held 
responsible. 
Our study has also brought out the correlation between lipid parameters and 
microalbuminuria. Although no correlation could be found between microalbuminuria 
and hypertriglyceridemia and hypercholesterolemia, the incidence of 
microalbuminuria is 1.93 times more likely for the patients who present with HDL 
values of less than30mg/dl. A similar inverse relationship between HDL and  
icroalbuminuria has been described in many studies77, 78, 79, 81, 82, 83. 
The incidence of microalbuminuria is significantly associated with the 
presence of retinopathy (p=0.073), peripheral neuropathy (p=0.009), ischemic heart 
disease  (p=0.011), hypertension (p=0.001) and body mass index (p=0.027) more 
than 25kg/m2. Peripheral neuropathy and hypertension have the most significant 
association with microalbuminuria. This association is not surprising since both 
hypertension and neuropathy are dependent on similar risk factors. It is also well 
known that retinopathy and microalbuminuria have a high concordance rate. Several 
studies have highlighted the occurrence of microalbuminuria as a marker of ischemic 
heart disease 78, 81, 83. Our study also underscores this point. Out of the total 38 
patients with microalbuminuria, 13 of them had ischemic heart disease. 
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SUMMARY 
 
 
ü We studied 100 Type II DM patients for detection of microalbuminuria through 
the dipstick method. 
 
ü The mean age between male and female and the mean age detection of DM 
is not statistically significant 
 
 
ü 9 patients had severe microalbuminuria between 100 and 300 mg/dl 
 
ü Incidence of microalbuminuria is 2.5 times more likely for the age group more 
than 50 years 
 
 
ü All patients with HbA1C 7 with  duration of DM > 15 years were positive for 
microalbuminuria 
 
ü Incidence of microalbuminuria is significantly associated with BMI > 25 kg/m^2  
 
 
ü Incidence of microalbuminuria is 1.9 times more in patients with HDL < 30 mg 
/dl 
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CONCLUSIONS 
 
 
  The incidence of microalbuminuria is estimated to be 38% in this study. 
 
  Microalbuminuria shows a direct relationship with increasing age of 
patients and increasing duration of diabetes mellitus since diagnosis. 
 
 
  A HbA1c value above 7% is associated with 50% or higherincidence of 
microalbuminuria. 
 
  Patients with a body mass index of more than 25kg/m2 have significant 
increasein the incidence of microalbuminuria. 
 
 
  Incidence of microalbuminuria is significantly associated with presence of 
hypertension, neuropathy, Ischemic heart disease, retinopathy and high body 
mass index. 
 
  Microalbuminuria is inversely associated with HDL. 
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PROFORMA 
Name:  
IP/OP No: 
Age:     Date of admission: 
Sex:      Date of discharge: 
Religion:    Marital status: 
Address: 
Occupation: 
 
 
Education: 
Income group: High/middle/poor 
 
CHIEF COMPLAINTS: 
Polyuria/  Polydipsia / Blurring of vision 
Weight loss / Tiredness Polyphagia 
Pruritus /Aches and pains Skin infections 
 
HISTORY OF PRESENTING ILLNESS 
 
1) Cardiovascular symptoms: 
Angina/ myocardial infarction/ exertional dyspnea /orthopnea 
PND /palpitations/ syncope /sweating/Swelling of feet 
 
2) Peripheral vascular symptoms: 
Intermittent claudication/ Gangrene /Impotence/ thrombophlebitis 
 
3) Cerebrovascular symptoms: 
Giddiness /headache/ vomiting/ transient ischemic attacks/Stroke 
 
4) Visual symptoms: 
Blurring of vision/ Progressive loss of vision /sudden loss of vision 
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5) Renal symptoms: 
a) Symptoms of urinary tract infection: 
Dysuria Fever with chills Flank pain 
b) Symptoms of nephropathy: 
Swelling of feet Puffiness of face Distension of abdomen 
Increasing sensitivity of insulin 
 
6) Symptoms of neurological complications: 
a) Symptoms of polyneuropathy: 
Tingling Numbness Paraesthesia Nocturnal pain 
Sensory ataxia Trophic ulcers Charcot joints 
b) Symptoms of mononeuropathy: 
Wrist drop Foot drop 
c) Cranial nerves: 
Diplopia Squint Deviation of the angle of mouth 
Inability to close the eyes 
d) Symptoms of radiculopathy: 
e) Symptoms of autonomic neuropathy 
Dysphagia vomiting Nocturnal diarrhea Syncope 
f) Symptoms of amyotrophy: 
Paraesthesia of the anterior thigh Thinning of proximal muscle 
Weakness of proximal muscles 
 
7) Symptoms of Diabetic skin complications: 
Recurrent skin infections Abscesses Carbuncles 
 
8) Gastro intestinal symptoms: 
Dysphagia Abdominal pain Nausea/Vomiting Diarrhea 
Weight loss Loss of appetite 
 
9) Genito urinary symptoms: 
Polyuria/Nocturia Balanoprosthitis Impotence Dysuria 
Discharge per urethra Discharge per vagina 
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DIABETES HISTORY 
Diabetes diagnosed in the year: 
Duration of Diabetes: 
Diabetes onset at the age of: 
Mode of onset of Diabetes: 
Family history of Diabetes: 
Drugs used for Diabetes: OHA / INSULIN/ INSULIN + OHA 
 
PAST HISTORY 
History of hypertension 
History of Angina / Myocardial infarction 
History of Transient ischemic attack / stroke 
 
PERSONAL HISTORY 
HABITS YES NO STOPPED 
Smoking 
Sweets 
Alcohol 
Tobacco 
Appetite /bowel /bladder 
 
FAMILY HISTORY 
MEMBERS PRESENT ABSENT 
Father 
Mother 
Sisters 
Sons 
Daughters 
Spouse 
Others: History of Hypertension, Ischemic heart disease , Cerebrovascular accidents 
Obesity and Sudden death 
 
OBSTETRIC AND GYNECOLOGICAL HISTORY 
Menarche/ Menopause 
Gravida/Para/Abortion/History of stillbirths/History of delivery of large babies 
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GENERAL PHYSICAL EXAMINATION 
1) BUILT: Well / moderately /poor/ emaciated 
2) WEIGHT: 
HEIGHT: 
BODY MASS INDEX: 
3) PULSE: 
4) BLOOD PRESSURE: 
5)PALLOR/EDEMA/CLUBBING/KOILONYCHIA/CYANOSIS/ICTERUS/LYMPHADENOP
ATHY 
6) JUGULAR VENOUS PULSE 
7) PERIPHERAL PULSE 
8) SKIN CHANGES: 
Diabetic dermopathy 
Acanthosis nigricans 
Scleroderma 
Xanthoma 
Fungal infection 
Skin tags 
9) EYES: 
Normal/ Xanthoma / Arcus / Cataract 
10) FUNDUS 
 
SYSTEMIC EXAMINATION 
 
1) CARDIOVASCULAR SYSTEM 
 INSPECTION 
 PALPATION 
 PERCUSSION 
 AUSCULTATION 
OTHER FINDINGS 
 
2) RESPIRATORY SYSTEM 
 INSPECTION 
 PALPATION 
 PERCUSSION 
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 AUSCULTATION 
 OTHER FINDINGS 
3) ABDOMEN 
 INSPECTION 
 PALPATION 
 PERCUSSION 
 AUSCULTATION 
 OTHER FINDINGS 
4) CENTRAL NERVOUS SYSTEM 
 HIGHER MENTAL FUNCTIONS 
 CRANIAL NERVES 
 MOTOR SYSTEM 
 NUTRITION 
 TONE 
 POWER 
 CO-ORDINATION 
 INVOLUNTARY MOVEMENTS 
 SENSORY SYSTEM 
TOUCH / PAIN / TEMPERATURE/VIBRATION / 
POSITION SENSE  
 DIABETIC RETINOPATHY: PRESENT/ ABSENT 
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INVESTIGATIONS 
1) URINE: 
 Macroalbuminuria 
 Microalbuminuria 
 Sugar 
 Microscopy 
 Ketone bodies 
2) BLOOD: 
 Fasting blood glucose 
 Post prandial blood glucose 
 Glycosylated hemoglobin: 
 Blood urea: 
 Serum creatinine: 
 Lipid profile 
1. Total cholesterol 
2. Triglycerides 
3. HDL 
4. LDL 
3) ELECTROCARDIOGRAM 
4) ECHOCARDIOGRAM (selected cases only) 
5) ABDOMINAL ULTRASONOGRAPHY 
 
 
DIAGNOSIS 
 
 
 
TREATMENT GIVEN: 
1) Diet 
2) Diet + OHA 
3) Diet + OHA + insulin 
4) Diet + insulin 
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SN  
AGE 
yr 
 
 
SEX 
AO 
/ 
DUR. 
yr 
 
 
 
Rx 
 
 
BMI 
 
MA 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
OTHERS 
1  
40 
 
M 
 
38/2 
 
OHA 
 
26.3 
 
- 
 
170 
250 
7.2 
 
34 
1.1 
 
235 
250 
 
155 
30 
- 
- 
- 
- 
- 
- 
2  
65 
 
M 
 
55 
10 
 
OHA 
 
19.8 
 
++ 
 
189 
232 
6.8 
 
23 
1 
 
170 
120 
 
118 
28 
- 
- 
- 
- 
+ 
- 
3  
68 
 
M 
 
55 
13 
 
OHA 
 
20.1 
 
+++ 
 
270 
355 
10.1 
 
36 
1 
 
189 
155 
 
126 
32 
+ 
+ 
- 
- 
- 
- 
4  
72 
 
M 
 
54 
18 
 
OHA 
INS 
 
16.4 
 
+++ 
 
221 
291 
9.8 
 
22 
0.9 
 
175 
145 
 
118 
28 
- 
- 
+ 
- 
- 
 
 
CVA 
5  
60 
 
M 
 
55 
5 
 
OHA 
 
17.8 
 
- 
 
173 
212 
7.8 
 
38 
0.8 
 
165 
135 
 
108 
30 
- 
- 
+ 
- 
- 
 
DIABETIC 
FOOT 
6  
58 
 
M 
 
50 
8 
 
OHA 
 
22.5 
 
- 
 
164 
250 
6.8 
 
33 
1.2 
 
184 
100 
 
 
132 
32 
- 
- 
- 
- 
- 
- 
7  
50 
 
F 
 
48 
2 
 
OHA 
 
18.2 
 
- 
 
160 
280 
7.6 
 
24 
1.2 
 
240 
285 
 
145 
38 
- 
- 
- 
- 
- 
 
DIABETIC 
FOOT 
8  
65 
 
M 
 
53 
12 
 
OHA 
INS 
 
26.3 
 
+ 
 
201 
294 
9.3 
 
26 
1.4 
 
212 
260 
 
130 
30 
- 
+ 
- 
+ 
- 
- 
9  
52 
 
F 
 
46 
6 
 
OHA 
 
30.1 
 
+ 
 
230 
289 
10.2 
 
27 
1 
 
240 
290 
 
146 
36 
- 
- 
- 
+ 
- 
- 
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SN  
AGE 
yr 
 
 
SEX 
AO 
/ 
DUR. 
yr 
 
 
 
Rx 
 
 
BMI 
 
M
A 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
OTHERS 
 
 
10 
 
 
43 
 
 
f 
 
 
39/4 
 
 
OHA 
 
 
18.4 
 
 
 
- 
 
214 
261 
6.9 
 
 
25 
0.8 
 
 
180 
100 
 
124 
36 
- 
- 
- 
- 
- 
- 
 
 
11 
 
 
46 
 
 
m 
 
 
44/2 
 
 
OHA 
 
 
22.5 
 
 
- 
 
210 
280 
6.8 
 
 
22 
0.8 
 
 
165 
105 
 
 
112 
32 
+ 
+ 
- 
- 
- 
- 
 
 
12 
 
 
70 
 
 
f 
 
54 
/16 
 
 
INS 
 
 
 
22.6 
 
 
 
+++ 
 
190 
286 
8.1 
 
26 
0.9 
 
192 
170 
 
 
128 
30 
- 
+ 
- 
- 
+ 
- 
 
 
13 
 
 
48 
 
 
M 
 
 
45/3 
 
 
OHA 
 
 
 
29.7 
 
 
 
- 
 
 
185 
270 
8.4 
 
 
38 
1.3 
 
144 
120 
 
 
92 
28 
 
- 
- 
- 
+ 
- 
- 
 
 
 
 
14 
 
 
60 
 
 
 
 
M 
 
 
58/2 
 
 
OHA 
 
 
 
21.9 
 
 
++ 
 
170 
250 
7.8 
 
 
34 
1.2 
 
 
180 
170 
 
 
120 
26 
 
- 
+ 
- 
- 
+ 
 
 
BPH 
 
 
15 
 
 
65 
 
 
M 
 
47/ 
18 
 
 
 
OHA 
 
 
24.3 
 
 
+++ 
 
210 
290 
8.4 
 
29 
1.1 
 
140 
85 
 
 
95 
28 
- 
- 
- 
- 
+ 
- 
 
 
 
16 
 
 
60 
 
 
M 
 
 
 
55/5 
 
 
 
OHA 
 
 
23 
 
 
- 
 
165 
260 
7.6 
 
30 
1.2 
 
 
200 
130 
 
146 
28 
- 
+ 
- 
- 
- 
- 
 
 
 
17 
 
 
40 
 
 
F 
 
 
38/2 
 
 
OHA 
 
 
28.3 
 
 
- 
 
192 
280 
9.2 
 
 
24 
1.1 
 
190 
90 
 
 
136 
36 
- 
- 
- 
- 
- 
- 
 
 
18 
 
 
44 
 
 
M 
 
 
40/4 
 
 
OHA 
 
 
21.8 
 
 
- 
 
160 
247 
6.8 
 
29 
1.2 
 
178 
170 
 
112 
32 
- 
- 
- 
- 
- 
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SN  
AGE 
yr 
 
 
SEX 
AO 
/ 
DUR. 
yr 
 
 
 
Rx 
 
 
BMI 
 
MA 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
OTHERS 
19 46 M 40/6 
 
OHA 26.2 
 
+ 180 
240 
7 
 
24 
0.9 
 
188 
190 
122 
28 
- 
- 
- 
- 
- 
- 
20 57 M 50/7 OHA 26.3 + 180 
212 
6.6 
34 
1.1 
 
186 
180 
 
120 
30 
- 
+ 
- 
- 
- 
- 
21 60 F 61/4 OHA 
 
22.6 
 
- 180 
256 
7.1 
 
24 
1.1 
165 
115 
 
108 
34 
- 
- 
- 
+ 
- 
- 
22 60 F 48 
12 
OHA 
 
19.8 
 
++ 
 
196 
272 
8.1 
 
28 
0.9 
 
160 
140 
 
102 
30 
 
- 
+ 
- 
+ 
- 
- 
 
 
23 48 
 
 
 
M 45/3 OHA 
 
20.3 - 154 
230 
6.4 
20 
0.8 
 
168 
130 
 
110 
32 
 
- 
+ 
- 
- 
- 
- 
24 40 F 38/2 
 
OHA 21.9 - 146 
212 
6.3 
28 
0.9 
212 
210 
 
134 
26 
- 
- 
- 
- 
- 
- 
 
25 44 F 
 
40/4 
 
OHA 22 - 149 
219 
6.4 
29 
1 
 
180 
120 
122 
34 
- 
- 
- 
- 
- 
Viral 
hepatitis 
 
26 80 F 68 
12 
OHA 18.2 ++ 214 
356 
10.2 
 
29 
1.2 
190 
130 
134 
30 
- 
- 
- 
+ 
+ 
- 
27 62 
 
 
M 58/4 OHA 22.6 - 241 
317 
9.5 
34 
1.3 
210 
140 
 
150 
32 
- 
+ 
- 
- 
- 
- 
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SN  
AGE 
yr 
 
 
SEX 
AO 
/ 
DUR. 
yr 
 
 
 
Rx 
 
 
BMI 
 
MA 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
OTHERS 
28 65 F 61/4 
 
OHA 30.1 
 
- 200 
290 
7.8 
 
42 
0.9 
 
185 
100 
135 
30 
- 
- 
- 
- 
- 
- 
29 55 M 51/4 OHA 24.2 - 210 
290 
7.4 
26 
1.1 
 
210 
180 
 
 
144 
30 
- 
+ 
- 
- 
- 
- 
30 50 M 40/ 
10 
OHA 
 
23.3 
 
++ 140 
196 
6.1 
29 
1 
175 
125 
 
118 
32 
- 
+ 
- 
- 
- 
- 
31 65 M 60/5 OHA 
 
23 
 
- 
 
156 
240 
7.4 
 
20 
1.1 
 
146 
100 
 
98 
28 
 
+ 
+ 
+ 
- 
+ 
- 
 
 
32 55 
 
 
 
M 53/3 OHA 
 
22.5 - 148 
240 
7 
 
29 
1.1 
 
155 
105 
 
106 
28 
 
- 
- 
- 
+ 
- 
Pneumonia 
33 40 m 38/2 
 
OHA 21.1 - 150 
226 
5.9 
31 
1.2 
224 
260 
 
144 
28 
- 
+ 
- 
- 
+ 
- 
 
34 45 
 
F 
 
42/3 
 
OHA 31.2 - 136 
200 
1.6 
28 
1 
 
250 
275 
155 
40 
- 
- 
- 
- 
- 
Lumbar 
sponylosis 
 
35 45 M 43/2 OHA 20.8 - 158 
250 
7.2 
 
29 
0.9 
140 
90 
 
96 
26 
- 
+ 
- 
- 
- 
OLD PTB 
36 55 
 
 
F 53/2 OHA 23.3 - 170 
300 
8.4 
33 
1 
224 
225 
149 
30 
- 
- 
- 
- 
- 
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SN  
AGE 
yr 
 
 
SEX 
AO 
/ 
DUR. 
yr 
 
 
 
Rx 
 
 
BMI 
 
M
A 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
OTHERS 
37 65 F 60/5 
 
OHA 22.4 
 
- 223 
247 
7.2 
25 
0.9 
 
165 
65 
122 
30 
- 
- 
- 
+ 
+ 
- 
38 72 M 66/6 OHA 20.8 - 220 
280 
8 
 
25 
0.8 
 
220 
230 
 
146 
28 
- 
- 
- 
+ 
- 
- 
39 70 F 53/ 
17 
OHA 
INS 
 
24.5 
 
++ 180 
260 
7.8 
 
29 
1.2 
200 
195 
 
132 
29 
+ 
+ 
- 
- 
- 
- 
40 66 M 62/4 OHA 
 
20.9 
 
- 
 
220 
280 
8 
34 
0.7 
 
196 
100 
 
144 
32 
 
- 
- 
+ 
- 
- 
- 
 
 
41 53 F 46/7 OHA 
 
21.6 - 212 
280 
8.2 
 
26 
0.9 
 
220 
260 
 
138 
30 
 
- 
- 
- 
- 
- 
 
42 80 F 70/ 
10 
 
OHA 32.5 ++ 280 
340 
10.8 
26 
0.8 
190 
120 
 
140 
26 
- 
- 
- 
+ 
+ 
- 
 
43 71 M 
 
55/ 
16 
 
INS 22.5 +++ 158 
267 
9.8 
34 
0.8 
 
130 
90 
88 
24 
- 
+ 
- 
- 
+ 
- 
 
44 48 F 44/4 OHA 21.3 - 190 
235 
7.6 
 
40 
1.2 
140 
130 
 
80 
34 
- 
- 
- 
- 
- 
OLD PTB 
45 61 M 57/4 OHA 23 - 180 
240 
7.2 
36 
1 
166 
70 
122 
30 
- 
+ 
- 
- 
- 
 
93 
 
SN  
AGE 
Yr 
 
 
SEX 
AO 
/ 
DUR. 
yr 
 
 
 
Rx 
 
 
BMI 
 
MA 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
OTHERS 
46 64 M 60/4 
 
OHA 18.8 
 
- 164 
232 
7 
32 
1.2 
 
182 
120 
130 
28 
- 
- 
- 
- 
 
+ 
- 
47 48 M 40/8 OHA 23.1 ++ 200 
280 
8.1 
 
20 
0.9 
 
181 
85 
 
136 
28 
- 
+ 
+ 
+ 
- 
- 
48 53 M 50/3 OHA 
 
21.6 
 
- 162 
240 
7.3 
 
27 
1.2 
213 
120 
 
160 
29 
- 
- 
- 
- 
- 
- 
49 48 M 44/4 OHA 
 
26.3 
 
- 
 
156 
242 
6.7 
 
30 
1 
 
201 
170 
 
140 
27 
 
- 
- 
- 
- 
- 
- 
 
 
50 52 
 
 
 
F 44/8 OHA 
 
24.9 ++ 149 
232 
6.2 
 
29 
1.3 
 
 
170 
120 
116 
30 
 
- 
+ 
- 
+ 
- 
- 
51 66 M 58/8 
 
OHA 24.3 
 
+++ 149 
232 
6.2 
27 
0.7 
 
161 
135 
102 
32 
- 
+ 
- 
- 
- 
- 
 
52 70 
 
M 
 
58/ 
12 
 
OHA 
INS 
30.4 ++ 186 
260 
7.1 
31 
0.8 
 
153 
115 
98 
32 
- 
+ 
+ 
- 
+ 
OLD CVA 
 
53 55 M 43/ 
12 
OHA 25 - 188 
239 
6.8 
27 
1.1 
181 
95 
 
132 
30 
- 
+ 
- 
- 
- 
OLD PTB 
54 57 
 
 
M 50/7 OHA 32.5 + 181 
252 
7.2 
28 
1.2 
187 
90 
140 
29 
- 
- 
- 
- 
- 
- 
94 
 
 
‘SN  
AGE 
Yr 
 
 
SEX 
AO 
/ 
DUR. 
yr 
 
 
 
Rx 
 
 
BMI 
 
M
A 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
OTHERS 
55 40 M 37/3 
 
OHA 21.9 
 
+ 129 
189 
6.1 
29 
0.7 
 
165 
115 
110 
32 
- 
- 
- 
- 
- 
- 
56 51 F 48/2 OHA 26.4 - 130 
198 
6 
 
23 
1.1 
 
160 
190 
 
112 
30 
- 
- 
- 
- 
- 
APD 
57 50 F 40/ 
10 
OHA 
INS 
 
28.2 
 
+++ 163 
280 
7 
 
39 
0.9 
274 
280 
 
178 
40 
- 
- 
- 
+ 
- 
- 
58 66 M 61/5 OHA 
INS 
 
21.9 
 
- 
 
166 
250 
6.8 
 
34 
1.2 
 
200 
185 
 
136 
27 
 
- 
- 
- 
+ 
- 
- 
 
 
59 45 
 
F 41/4 OHA 
 
21.5 - 160 
240 
6.6 
 
28 
0.9 
 
 
158 
120 
102 
32 
 
- 
- 
- 
- 
- 
- 
60 66 F 58/8 
 
OHA 19.8 ++ 205 
380 
8.2 
27 
1.3 
 
258 
270 
178 
26 
- 
- 
- 
+ 
+ 
- 
61 57 
 
F 
 
47/ 
10 
 
OHA 
INS 
24.5 ++ 174 
250 
7.3 
19 
1.1 
 
291 
285 
196 
38 
+ 
- 
- 
- 
+ 
 
- 
62 52 F 43/9 OHA 
INS 
21.3 ++ 235 
310 
8.9 
 
18 
1.2 
280 
310 
 
186 
32 
- 
+ 
- 
+ 
- 
- 
63 40 
 
 
M 38/2 OHA 19.8 - 127 
203 
5.9 
18 
0.8 
200 
180 
134 
30 
- 
- 
- 
- 
- 
- 
95 
 
SN  
AGE 
Yr 
 
 
SEX 
AO 
/ 
DUR. 
yr 
 
 
 
Rx 
 
 
BMI 
 
MA 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
OTHERS 
64 45 M 43/2 
 
OHA 25 
 
- 130 
201 
5.9 
 
32 
0.9 
 
250 
225 
176 
29 
- 
- 
- 
- 
- 
APD 
65 55 F 50/5 OHA 21.9 - 140 
180 
6.1 
 
23 
0.8 
 
160 
130 
 
102 
32 
+ 
- 
- 
- 
- 
- 
66 38 F 35/3 OHA 
 
26.2 
 
+ 210 
257 
7.2 
 
22 
0.8 
212 
170 
 
140 
38 
- 
- 
- 
- 
- 
- 
67 60 F 55/5 OHA 
 
22.5 
 
- 
 
190 
280 
8.1 
 
29 
1.1 
 
204 
120 
 
148 
32 
 
- 
+ 
- 
- 
- 
- 
 
 
68 35 
 
 
 
M 30/7 OHA 
 
31.2 + 149 
190 
5.9 
 
32 
1.1 
 
222 
245 
 
143 
30 
 
- 
+ 
- 
- 
- 
- 
69 47 M 44/3 
 
OHA 26.3 - 200 
251 
7.8 
22 
0.9 
219 
260 
138 
29 
- 
- 
- 
- 
- 
APD 
 
70 50 
 
M 
 
48/2 
 
OHA 22.1 - 141 
210 
6 
33 
1.1 
 
190 
105 
140 
29 
- 
+ 
- 
- 
- 
 
- 
71 55 F 43/ 
12 
OHA 31.2 ++ 195 
260 
8 
 
39 
0.9 
175 
190 
 
110 
27 
- 
- 
- 
+ 
+ 
- 
72 78 
 
 
M 60/ 
18 
OHA 26.7 +++ 210 
292 
9.2 
43 
1.3 
161 
110 
112 
27 
- 
+ 
+ 
- 
+ 
- 
 
96 
 
SN  
AGE 
yr 
 
 
SEX 
AO 
/ 
DUR. 
yr 
 
 
 
Rx 
 
 
BMI 
 
MA 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
OTHERS 
73 33 F 32/1 
 
OHA 25 
 
- 155 
230 
6.8 
 
29 
0.9 
 
200 
160 
130 
28 
- 
+ 
- 
- 
- 
 
74 45 F 39/6 OHA 22 + 167 
198 
6.3 
 
44 
1.4 
 
155 
115 
 
103 
29 
- 
- 
- 
+ 
- 
 
75 65 M 62/3 OHA 
 
22.5 
 
- 200 
250 
6.8 
 
32 
1.2 
166 
140 
 
108 
30 
+ 
- 
- 
- 
- 
 
76 37 M 35/2 OHA 
 
32.5 
 
- 
 
170 
250 
7.2 
 
38 
1.2 
 
178 
185 
 
109 
32 
 
- 
- 
- 
- 
- 
 
 
 
77 45 
 
 
 
M 37/8 OHA 
 
21.9 - 165 
291 
7.7 
 
28 
1.1 
 
190 
125 
 
129 
36 
 
- 
- 
- 
- 
- 
 
78 36 M 33/3 
 
OHA 23.3 - 161 
245 
6.8 
22 
1.1 
215 
115 
 
160 
32 
- 
+ 
- 
- 
- 
 
 
79 55 
 
M 
 
49/6 
 
OHA 24 + 176 
290 
8 
40 
0.9 
 
170 
140 
112 
30 
- 
- 
- 
- 
- 
 
 
80 55 M 52/3 OHA 23.2 - 190 
290 
7.9 
 
39 
1.1 
168 
140 
 
108 
29 
- 
+ 
- 
- 
- 
 
81 52 
 
 
M 50/2 OHA 23 - 166 
270 
8 
26 
1.3 
265 
280 
180 
34 
+ 
- 
- 
+ 
+ 
 
 
97 
 
SN  
AGE 
Yr 
 
 
SEX 
AO 
/ 
DUR. 
yr 
 
 
 
Rx 
 
 
BMI 
 
MA 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
OTHERS 
82 40 M  
39/1 
OHA  
22.6 
-  
145 
190 
5.8 
 
28 
0.8 
160 
110 
104 
34 
- 
+ 
- 
- 
- 
- 
83 62 M 50/ 
12 
OHA 
INS 
24.7 ++ 210 
290 
8.2 
 
29 
1.3 
 
180 
215 
 
108 
29 
+ 
- 
- 
+ 
+ 
- 
84 55 M 52/3 OHA 
 
22.5 
 
- 140 
242 
6.2 
 
27 
1.2 
200 
220 
 
130 
26 
- 
+ 
- 
- 
- 
 
85 68 F 62/6 OHA 
 
20.8 
 
- 
 
168 
250 
6.6 
 
40 
1.1 
 
206 
225 
 
127 
34 
 
- 
- 
- 
- 
- 
 
 
 
86 72 
 
 
 
F 66/6 INS 
 
29.7 + 178 
212 
6 
 
42 
1.3 
 
153 
115 
 
98 
32 
 
+ 
+ 
- 
- 
- 
 
87 78 F 65/ 
13 
 
OHA 
INS 
20.3 ++ 220 
320 
10.7 
22 
1.3 
140 
110 
 
88 
30 
+ 
+ 
- 
- 
+ 
 
 
88 60 
 
F 
 
57/3 
 
INS 20.1 - 129 
190 
6 
33 
1 
 
176 
130 
118 
32 
- 
- 
+ 
- 
- 
 
 
89 60 F 55/5 OHA 
INS 
22.6 - 145 
184 
5.9 
 
22 
1.2 
218 
280 
 
128 
34 
- 
- 
+ 
- 
- 
 
90 44 
 
 
M 43/1 OHA 20 - 180 
263 
7.2 
23 
1 
150 
135 
93 
30 
- 
- 
- 
- 
- 
 
 
98 
 
SN  
AGE 
yr 
 
 
SEX 
AO 
/ 
DUR. 
yr 
 
 
 
Rx 
 
 
BMI 
 
MA 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
OTHERS 
 
 
91 
 
 
60 
 
 
M 
 
 
55/5 
 
 
 
OHA 
 
 
18.8 
 
 
 
- 
 
170 
219 
6.4 
 
 
 
21 
0.9 
 
 
 
184 
160 
 
 
121 
31 
- 
+ 
- 
- 
- 
- 
 
 
92 
 
 
75 
 
 
M 
 
 
57/ 
18 
 
 
OHA 
INS 
 
 
22.4 
 
 
+++ 
 
272 
348 
9.2 
 
 
29 
1.1 
 
 
234 
190 
 
 
168 
28 
+ 
+ 
- 
- 
+ 
- 
 
 
93 
 
 
74 
 
 
F 
 
 
60/ 
14 
 
 
OHA 
 
 
 
21.1 
 
 
 
++ 
 
200 
326 
8.8 
 
 
32 
0.9 
 
172 
155 
 
 
108 
33 
- 
+ 
- 
- 
+ 
 
 
 
94 
 
 
55 
 
 
F 
 
 
53/2 
 
 
OHA 
 
 
 
19.8 
 
 
 
- 
 
 
172 
250 
7.4 
 
 
22 
1.1 
 
 
210 
210 
 
 
138 
30 
 
- 
- 
- 
- 
- 
 
 
 
 
 
95 
 
 
35 
 
 
 
F 
 
 
33/2 
 
 
OHA 
 
 
 
24.2 
 
 
- 
 
195 
240 
6.4 
 
 
31 
1.3 
 
 
175 
145 
 
 
108 
38 
 
- 
- 
- 
- 
- 
 
 
 
96 
 
 
50 
 
 
F 
 
 
48/2 
 
 
 
OHA 
 
 
21.9 
 
 
- 
 
165 
230 
6.8 
 
33 
1.2 
 
145 
120 
 
 
88 
33 
- 
- 
- 
- 
- 
 
 
 
 
97 
 
 
36 
 
 
 
F 
 
 
 
34/2 
 
 
 
OHA 
 
 
19.5 
 
 
- 
 
190 
230 
6.6 
 
39 
0.9 
 
 
150 
110 
 
86 
42 
- 
- 
- 
- 
- 
 
 
 
 
98 
 
 
40 
 
 
F 
 
 
39/1 
 
 
OHA 
 
 
20.9 
 
 
- 
 
182 
270 
7.2 
 
42 
1 
 
181 
115 
 
 
122 
36 
- 
- 
- 
+ 
- 
 
 
 
99 
 
 
38 
 
 
 
 
M 
 
 
35/3 
 
 
OHA 
 
 
21.9 
 
 
- 
 
165 
230 
6.8 
 
22 
1.2 
 
 
150 
90 
 
108 
24 
+ 
- 
- 
- 
+ 
 
 
99 
 
 
 
  
 
 
SN 
 
 
AGE 
Yr 
 
 
SEX 
AO 
/ 
DUR 
Yr 
 
 
Rx 
 
 
BMI 
M 
A 
L 
B 
 
FBS 
PPBS 
HBA1C 
 
UREA 
/ 
CREA 
 
CHO 
/ 
TGL 
 
LDL 
/ 
HDL 
RP 
PN 
PVD 
IHD 
HT 
 
 
OTHERS 
 
 
100 
 
 
55 
 
 
F 
 
 
44/ 
11 
 
 
OHA 
 
 
24.2 
 
 
++ 
 
215 
321 
8.9 
 
 
41 
1 
 
 
161 
130 
 
 
105 
30 
+ 
- 
- 
- 
+ 
- 
 
100 
 
KEYS TO MASTER SHEET 
AO AGE OF ONSET OF DM 
DUR DURATION OF DM 
MALB MICROALBUMINURIA 
FBS FASTING BLOOD SUGAR 
PPBS POST PRANDIAL BLOOD SUGAR 
HbA1C GLYCOSYLATED HAEMOGLOBIN 
CREA CREATININE 
BMI BODY MASS INDEX 
CHO TOTAL CHOLESTROL 
RP RETINOPATHY 
PN PERIPHERAL NEUROPATHY 
IHD ISCHEMIC HEART DISEASE 
PVD PERIPHERAL VASCULAR DISEASE 
HT HYPERTENSION 
